{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:21:54Z","timestamp":1793305314441,"version":"4.5.0"},"reference-count":741,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"am","delay-in-days":346,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["R56HL156806"],"award-info":[{"award-number":["R56HL156806"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association Inc","doi-asserted-by":"publisher","award":["24PRE1181407"],"award-info":[{"award-number":["24PRE1181407"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK135817"],"award-info":[{"award-number":["R01DK135817"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.pharmr.2025.100065","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T19:29:08Z","timestamp":1747250948000},"page":"100065","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmaceutical perspectives on oligonucleotide therapeutics and delivery systems"],"prefix":"10.1016","volume":"77","author":[{"given":"Dalton W.","family":"Staller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0877-4521","authenticated-orcid":false,"given":"Flobater I.","family":"Gawargi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6190-3777","authenticated-orcid":false,"given":"Sanjali S.","family":"Panigrahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paras K.","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3588-0434","authenticated-orcid":false,"given":"Ram I.","family":"Mahato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib1","first-page":"134","article-title":"Gregor Mendel and the principles of inheritance","volume":"1","author":"Miko","year":"2008","journal-title":"Nat Educ"},{"key":"10.1016\/j.pharmr.2025.100065_bib2","article-title":"Versuche \u00fcber Pflanzen-Hybriden","author":"Mendel","year":"1866","journal-title":"Im Verlage des Vereines"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib3","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/BF03401625","article-title":"The incidence of alkaptonuria: a study in chemical individuality. 1902","volume":"2","author":"Garrod","year":"1996","journal-title":"Mol Med"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib4","first-page":"169","article-title":"Barbara McClintock and the discovery of jumping genes (transposons)","volume":"1","author":"Pray","year":"2008","journal-title":"Nat Educ"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib5","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s12276-022-00757-5","article-title":"RNA therapy: rich history, various applications and unlimited future prospects","volume":"54","author":"Kim","year":"2022","journal-title":"Exp Mol Med"},{"issue":"14","key":"10.1016\/j.pharmr.2025.100065_bib6","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1021\/ja01595a086","article-title":"A new two stranded helical structure: polyadenylic acid and polyuridylic acid","volume":"78","author":"Rich","year":"1956","journal-title":"J Am Chem Soc"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib7","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1073\/pnas.75.1.280","article-title":"Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide","volume":"75","author":"Zamecnik","year":"1978","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5543","key":"10.1016\/j.pharmr.2025.100065_bib8","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1126\/science.1065062","article-title":"An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans","volume":"294","author":"Lau","year":"2001","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100065_bib9","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/0092-8674(93)90529-Y","article-title":"The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14","volume":"75","author":"Lee","year":"1993","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100065_bib10","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/0092-8674(93)90530-4","article-title":"Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans","volume":"75","author":"Wightman","year":"1993","journal-title":"Cell"},{"issue":"6808","key":"10.1016\/j.pharmr.2025.100065_bib11","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/35040556","article-title":"Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA","volume":"408","author":"Pasquinelli","year":"2000","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.pharmr.2025.100065_bib12","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1101\/gad.1004402","article-title":"MicroRNAs in plants","volume":"16","author":"Reinhart","year":"2002","journal-title":"Genes Dev"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100065_bib13","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1073\/pnas.74.8.3171","article-title":"Spliced segments at the 5\u2032 terminus of adenovirus 2 late mRNA","volume":"74","author":"Berget","year":"1977","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0092-8674(77)90180-5","article-title":"An amazing sequence arrangement at the 5\u2032 ends of adenovirus 2 messenger RNA","volume":"12","author":"Chow","year":"1977","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib15","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1101\/gad.1048803","article-title":"Pre-mRNA splicing and human disease","volume":"17","author":"Faustino","year":"2003","journal-title":"Genes Dev"},{"issue":"18","key":"10.1016\/j.pharmr.2025.100065_bib16","doi-asserted-by":"crossref","first-page":"8673","DOI":"10.1073\/pnas.90.18.8673","article-title":"Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides","volume":"90","author":"Dominski","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4949 Pt 1","key":"10.1016\/j.pharmr.2025.100065_bib17","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1690918","article-title":"Direct gene transfer into mouse muscle in vivo","volume":"247","author":"Wolff","year":"1990","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100065_bib18","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/eji.1830230749","article-title":"Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA","volume":"23","author":"Martinon","year":"1993","journal-title":"Eur J Immunol"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100065_bib19","first-page":"1397","article-title":"Characterization of a messenger RNA polynucleotide vaccine vector","volume":"55","author":"Conry","year":"1995","journal-title":"Cancer Res"},{"issue":"7011","key":"10.1016\/j.pharmr.2025.100065_bib20","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nature03001","article-title":"Finishing the euchromatic sequence of the human genome","volume":"431","year":"2004","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib21","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1042\/EBC20180038","article-title":"Understanding biochemistry: structure and function of nucleic acids","volume":"63","author":"Minchin","year":"2019","journal-title":"Essays Biochem"},{"key":"10.1016\/j.pharmr.2025.100065_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbpa.2024.102479","article-title":"RNA nanotechnology on the horizon: self-assembly, chemical modifications, and functional applications","volume":"81","author":"Stewart","year":"2024","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.pharmr.2025.100065_bib23","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1016\/j.csbj.2022.05.041","article-title":"Secondary structures in RNA synthesis, splicing and translation","volume":"20","author":"Georgakopoulos-Soares","year":"2022","journal-title":"Comput Struct Biotechnol J"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100065_bib24","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1007\/s00894-010-0951-x","article-title":"RNA and protein 3D structure modeling: similarities and differences","volume":"17","author":"Rother","year":"2011","journal-title":"J Mol Model"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100065_bib25","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1021\/ar200098t","article-title":"The molecular interactions that stabilize RNA tertiary structure: RNA motifs, patterns, and networks","volume":"44","author":"Butcher","year":"2011","journal-title":"ACC Chem Res"},{"key":"10.1016\/j.pharmr.2025.100065_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15470","article-title":"Structure of the quaternary complex between SRP, SR, and translocon bound to the translating ribosome","volume":"8","author":"Jomaa","year":"2017","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib27","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tibs.2015.02.004","article-title":"RNA quaternary structure and global symmetry","volume":"40","author":"Jones","year":"2015","journal-title":"Trends Biochem Sci"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100065_bib28","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1101\/gad.5.11.2108","article-title":"The cap and poly(A) tail function synergistically to regulate mRNA translational efficiency","volume":"5","author":"Gallie","year":"1991","journal-title":"Genes Dev"},{"issue":"6675","key":"10.1016\/j.pharmr.2025.100065_bib29","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/33192","article-title":"Dual function of the messenger RNA cap structure in poly(A)-tail-promoted translation in yeast","volume":"392","author":"Preiss","year":"1998","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib30","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.bbrc.2018.01.085","article-title":"Biogenic triamine and tetraamine activate core catalytic ability of Tetrahymena group I ribozyme in the absence of its large activator module","volume":"496","author":"Gulshan","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100065_bib31","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.coph.2010.07.002","article-title":"Therapeutic applications of ribozymes and riboswitches","volume":"10","author":"Mulhbacher","year":"2010","journal-title":"Curr Opin Pharmacol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib32","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jmb.2008.07.020","article-title":"Single VS. Single VS ribozyme molecules reveal dynamic and hierarchical folding toward catalysis","volume":"382","author":"Pereira","year":"2008","journal-title":"J Mol Biol"},{"issue":"4947","key":"10.1016\/j.pharmr.2025.100065_bib33","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1126\/science.2107573","article-title":"Ribozymes as potential anti-HIV-1 therapeutic agents","volume":"247","author":"Sarver","year":"1990","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib34","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2307\/3869076","article-title":"Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans","volume":"2","author":"Napoli","year":"1990","journal-title":"Plant Cell"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib35","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/nbt936","article-title":"Rational siRNA design for RNA interference","volume":"22","author":"Reynolds","year":"2004","journal-title":"Nat Biotechnol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib36","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1101\/gad.862301","article-title":"RNA interference is mediated by 21-and 22-nucleotide RNAs","volume":"15","author":"Elbashir","year":"2001","journal-title":"Genes Dev"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100065_bib37","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/nsmb.1673","article-title":"Structural insights into RNA processing by the human RISC-loading complex","volume":"16","author":"Wang","year":"2009","journal-title":"Nat Struct Mol Biol"},{"issue":"26","key":"10.1016\/j.pharmr.2025.100065_bib38","doi-asserted-by":"crossref","first-page":"5850","DOI":"10.1016\/j.febslet.2005.08.071","article-title":"Small RNA asymmetry in RNAi: function in RISC assembly and gene regulation","volume":"579","author":"Hutvagner","year":"2005","journal-title":"FEBS Lett"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib39","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.molcel.2010.05.015","article-title":"Hsc70\/Hsp90 chaperone machinery mediates ATP-dependent RISC loading of small RNA duplexes","volume":"39","author":"Iwasaki","year":"2010","journal-title":"Mol Cell"},{"key":"10.1016\/j.pharmr.2025.100065_bib40","unstructured":"The Nobel Prize. The Nobel Assembly at Karolinska Institutet; 2024."},{"key":"10.1016\/j.pharmr.2025.100065_bib41","first-page":"D148","article-title":"miRTarBase 2020: updates to the experimentally validated microRNA-target interaction database","volume":"48","author":"Huang","year":"2020","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib42","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S0955-0674(00)00212-X","article-title":"Pre-mRNA splicing in the new millennium","volume":"13","author":"Hastings","year":"2001","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.pharmr.2025.100065_bib43","first-page":"27","article-title":"Employment opportunities for non-coding RNAs","volume":"567","author":"Morey","year":"2004","journal-title":"FEBS Lett"},{"issue":"24","key":"10.1016\/j.pharmr.2025.100065_bib44","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.4161\/cc.5.24.3579","article-title":"A new role for microRNA pathways: modulation of degeneration induced by pathogenic human disease proteins","volume":"5","author":"Bilen","year":"2006","journal-title":"Cell Cycle"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100065_bib45","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.tcb.2015.07.011","article-title":"The functions of microRNAs: mRNA decay and translational repression","volume":"25","author":"Iwakawa","year":"2015","journal-title":"Trends Cell Biol"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100065_bib46","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nrg3965","article-title":"Towards a molecular understanding of microRNA-mediated gene silencing","volume":"16","author":"Jonas","year":"2015","journal-title":"Nat Rev Genet"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib47","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nrm2321","article-title":"Argonaute proteins: key players in RNA silencing","volume":"9","author":"Hutvagner","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100065_bib48","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrg3462","article-title":"Argonaute proteins: functional insights and emerging roles","volume":"14","author":"Meister","year":"2013","journal-title":"Nat Rev Genet"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib49","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.cell.2018.03.006","article-title":"Metazoan microRNAs","volume":"173","author":"Bartel","year":"2018","journal-title":"Cell"},{"issue":"7216","key":"10.1016\/j.pharmr.2025.100065_bib50","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/nature07299","article-title":"MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation","volume":"455","author":"Tay","year":"2008","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100065_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0002126","article-title":"Systematic identification of mRNAs recruited to argonaute 2 by specific microRNAs and corresponding changes in transcript abundance","volume":"3","author":"Hendrickson","year":"2008","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib52","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/cvr\/cvn156","article-title":"Role of microRNAs in vascular diseases, inflammation, and angiogenesis","volume":"79","author":"Urbich","year":"2008","journal-title":"Cardiovasc Res"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100065_bib53","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/s41576-023-00611-y","article-title":"microRNAs in action: biogenesis, function and regulation","volume":"24","author":"Shang","year":"2023","journal-title":"Nat Rev Genet"},{"issue":"46","key":"10.1016\/j.pharmr.2025.100065_bib54","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abd6764","article-title":"Redox-responsive nanoplatform for codelivery of miR-519c and gemcitabine for pancreatic cancer therapy","volume":"6","author":"Xin","year":"2020","journal-title":"Sci Adv"},{"key":"10.1016\/j.pharmr.2025.100065_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122049","article-title":"Anti-miR-96 and Hh pathway inhibitor MDB5 synergistically ameliorate alcohol-associated liver injury in mice","volume":"295","author":"Kumar","year":"2023","journal-title":"Biomaterials"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100065_bib56","doi-asserted-by":"crossref","first-page":"4058","DOI":"10.1016\/j.ymthe.2024.09.036","article-title":"Anti-CLL1 liposome loaded with miR-497-5p and venetoclax as a novel therapeutic strategy in acute myeloid leukemia","volume":"32","author":"Pan","year":"2024","journal-title":"Mol Ther"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib57","first-page":"683","article-title":"Induction of autophagy markers is associated with attenuation of miR-133a in diabetic heart failure patients undergoing mechanical unloading","volume":"7","author":"Nandi","year":"2015","journal-title":"Am J Transl Res"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100065_bib58","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.2337\/db16-0023","article-title":"Lack of miR-133a decreases contractility of diabetic hearts: a role for novel cross talk between tyrosine aminotransferase and tyrosine hydroxylase","volume":"65","author":"Nandi","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmr.2025.100065_bib59","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3389\/fcvm.2019.00045","article-title":"Transgenic expression of miR-133a in the diabetic akita heart prevents cardiac remodeling and cardiomyopathy","volume":"6","author":"Kambis","year":"2019","journal-title":"Front Cardiovasc Med"},{"issue":"7099","key":"10.1016\/j.pharmr.2025.100065_bib60","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nature04916","article-title":"A novel class of small RNAs bind to MILI protein in mouse testes","volume":"442","author":"Aravin","year":"2006","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100065_bib61","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.cell.2007.01.043","article-title":"Discrete small RNA-generating loci as master regulators of transposon activity in Drosophila","volume":"128","author":"Brennecke","year":"2007","journal-title":"Cell"},{"issue":"7099","key":"10.1016\/j.pharmr.2025.100065_bib62","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/nature04917","article-title":"A germline-specific class of small RNAs binds mammalian Piwi proteins","volume":"442","author":"Girard","year":"2006","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib63","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cell.2007.03.026","article-title":"A role for Piwi and piRNAs in germ cell maintenance and transposon silencing in Zebrafish","volume":"129","author":"Houwing","year":"2007","journal-title":"Cell"},{"issue":"5785","key":"10.1016\/j.pharmr.2025.100065_bib64","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1126\/science.1129333","article-title":"A distinct small RNA pathway silences selfish genetic elements in the germline","volume":"313","author":"Vagin","year":"2006","journal-title":"Science"},{"issue":"13","key":"10.1016\/j.pharmr.2025.100065_bib65","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0960-9822(01)00299-8","article-title":"Double-stranded RNA-mediated silencing of genomic tandem repeats and transposable elements in the D. melanogaster germline","volume":"11","author":"Aravin","year":"2001","journal-title":"Curr Biol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib66","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/genetics\/139.2.697","article-title":"Flamenco, a gene controlling the gypsy retrovirus of Drosophila melanogaster","volume":"139","author":"Prud'homme","year":"1995","journal-title":"Genetics"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib67","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1534\/genetics.166.3.1313","article-title":"Evidence for a piwi-dependent RNA silencing of the gypsy endogenous retrovirus by the Drosophila melanogaster flamenco gene","volume":"166","author":"Sarot","year":"2004","journal-title":"Genetics"},{"key":"10.1016\/j.pharmr.2025.100065_bib68","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1101\/gad.1454806","article-title":"Specific association of Piwi with rasiRNAs derived from retrotransposon and heterochromatic regions in the Drosophila genome","volume":"20","author":"Saito","year":"2006","journal-title":"Genes Dev"},{"issue":"13","key":"10.1016\/j.pharmr.2025.100065_bib69","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1101\/gad.1434406","article-title":"A novel class of small RNAs in mouse spermatogenic cells","volume":"20","author":"Grivna","year":"2006","journal-title":"Genes Dev"},{"issue":"5785","key":"10.1016\/j.pharmr.2025.100065_bib70","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1126\/science.1130164","article-title":"Characterization of the piRNA complex from rat testes","volume":"313","author":"Lau","year":"2006","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib71","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.molcel.2008.06.002","article-title":"PRG-1 and 21U-RNAs interact to form the piRNA complex required for fertility in C. elegans","volume":"31","author":"Batista","year":"2008","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib72","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.molcel.2008.06.003","article-title":"Piwi and piRNAs act upstream of an endogenous siRNA pathway to suppress Tc3 transposon mobility in the Caenorhabditis elegans germline","volume":"31","author":"Das","year":"2008","journal-title":"Mol Cell"},{"issue":"22","key":"10.1016\/j.pharmr.2025.100065_bib73","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.3390\/ijms20225573","article-title":"Mechanisms and functions of long non-coding RNAs at multiple regulatory levels","volume":"20","author":"Zhang","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib74","first-page":"17","article-title":"Long non-coding RNAs in the regulation of gene expression: physiology and disease","volume":"5","author":"Fernandes","year":"2019","journal-title":"Noncoding RNA"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib75","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s13059-017-1348-2","article-title":"The multidimensional mechanisms of long noncoding RNA function","volume":"18","author":"Marchese","year":"2017","journal-title":"Genome Biol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib76","first-page":"3","article-title":"Besides pathology: long non-coding RNA in cell and tissue homeostasis","volume":"4","author":"Salviano-Silva","year":"2018","journal-title":"Noncoding RNA"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib77","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ncrna.2023.02.009","article-title":"The role of long non-coding RNAs in the development of adipose cells","volume":"8","author":"Sufianov","year":"2023","journal-title":"Noncoding RNA Res"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib78","first-page":"36","article-title":"Long non-coding RNA (lncRNA) roles in cell biology, neurodevelopment and neurological disorders","volume":"7","author":"Aliperti","year":"2021","journal-title":"Noncoding RNA"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100065_bib79","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41580-022-00566-8","article-title":"Long non-coding RNAs: definitions, functions, challenges and recommendations","volume":"24","author":"Mattick","year":"2023","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib80","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00424-021-02641-z","article-title":"Long non-coding RNAs: novel regulators of cellular physiology and function","volume":"474","author":"Oo","year":"2022","journal-title":"Pflugers Arch"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100065_bib81","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.ymthe.2023.02.008","article-title":"Roles of lncRNAs in brain development and pathogenesis: emerging therapeutic opportunities","volume":"31","author":"Srinivas","year":"2023","journal-title":"Mol Ther"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib82","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41580-020-00315-9","article-title":"Gene regulation by long non-coding RNAs and its biological functions","volume":"22","author":"Statello","year":"2021","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib83","first-page":"3","article-title":"The role of lncRNAs in gene expression regulation through mRNA stabilization","volume":"7","author":"Sebastian-delaCruz","year":"2021","journal-title":"Noncoding RNA"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100065_bib84","doi-asserted-by":"crossref","first-page":"925","DOI":"10.4161\/rna.24604","article-title":"On the classification of long non-coding RNAs","volume":"10","author":"Ma","year":"2013","journal-title":"RNA Biol"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagrm.2019.194419","article-title":"The how and why of lncRNA function: an innate immune perspective","volume":"1863","author":"Robinson","year":"2020","journal-title":"Biochim Biophys Acta Gene Regul Mech"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib86","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1080\/15476286.2023.2242649","article-title":"Inefficient splicing of long non-coding RNAs is associated with higher transcript complexity in human and mouse","volume":"20","author":"Basu","year":"2023","journal-title":"RNA Biol"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100065_bib87","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.molcel.2011.08.018","article-title":"Molecular mechanisms of long noncoding RNAs","volume":"43","author":"Wang","year":"2011","journal-title":"Mol Cell"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100065_bib88","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1080\/15476286.2015.1063770","article-title":"Long non-coding RNA and chromatin remodeling","volume":"12","author":"Han","year":"2015","journal-title":"RNA Biol"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100065_bib89","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/bies.201100084","article-title":"Long non-coding RNA modifies chromatin: epigenetic silencing by long non-coding RNAs","volume":"33","author":"Saxena","year":"2011","journal-title":"Bioessays"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100065_bib90","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.gendis.2022.04.007","article-title":"Long noncoding RNA XIST: Mechanisms for X chromosome inactivation, roles in sex-biased diseases, and therapeutic opportunities","volume":"9","author":"Li","year":"2022","journal-title":"Genes Dis"},{"issue":"16","key":"10.1016\/j.pharmr.2025.100065_bib91","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.3390\/cancers15164160","article-title":"The long non-coding RNA ANRIL in cancers","volume":"15","author":"Sanchez","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib92","doi-asserted-by":"crossref","DOI":"10.1080\/19491034.2024.2350182","article-title":"LncRNAs, nuclear architecture and the immune response","volume":"15","author":"Montano","year":"2024","journal-title":"Nucleus"},{"issue":"28","key":"10.1016\/j.pharmr.2025.100065_bib93","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1038\/s41388-024-03068-3","article-title":"MUC1-C regulates NEAT1 lncRNA expression and paraspeckle formation in cancer progression","volume":"43","author":"Bhattacharya","year":"2024","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib94","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/15384101.2020.1711578","article-title":"LncRNA NEAT1 affects inflammatory response by targeting miR-129-5p and regulating Notch signaling pathway in epilepsy","volume":"19","author":"Wan","year":"2020","journal-title":"Cell Cycle"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib95","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0090-4295(95)80030-1","article-title":"The imprinted H19 gene as a tumor marker in bladder carcinoma","volume":"45","author":"Ariel","year":"1995","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib96","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0014-5793(95)01074-O","article-title":"The expression of the imprinted H19 and IGF-2 genes in human bladder carcinoma","volume":"374","author":"Elkin","year":"1995","journal-title":"FEBS Lett"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100065_bib97","first-page":"1193","article-title":"Frequent loss of imprinting of the H19 gene is often associated with its overexpression in human lung cancers","volume":"10","author":"Kondo","year":"1995","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib98","first-page":"480","article-title":"Loss of H19 imprinting in esophageal cancer","volume":"56","author":"Hibi","year":"1996","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib99","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/sj.onc.1201175","article-title":"The expression of the imprinted genes H19 and IGF-2 in choriocarcinoma cell lines. Is H19 a tumor suppressor gene?","volume":"15","author":"Lustig-Yariv","year":"1997","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib100","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.bbamcr.2010.01.010","article-title":"The oncofetal H19 RNA connection: hypoxia, p53 and cancer","volume":"1803","author":"Matouk","year":"2010","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib101","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.canlet.2016.08.009","article-title":"Long non-coding RNA H19 regulates glioma angiogenesis and the biological behavior of glioma-associated endothelial cells by inhibiting microRNA-29a","volume":"381","author":"Jia","year":"2016","journal-title":"Cancer Lett"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib102","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.canlet.2013.01.033","article-title":"Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression","volume":"333","author":"Luo","year":"2013","journal-title":"Cancer Lett"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib103","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.gendis.2023.02.008","article-title":"Long noncoding RNA (lncRNA) H19: An essential developmental regulator with expanding roles in cancer, stem cell differentiation, and metabolic diseases","volume":"10","author":"Liao","year":"2023","journal-title":"Genes Dis"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100065_bib104","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.7150\/ijbs.62573","article-title":"LncRNA H19: a novel oncogene in multiple cancers","volume":"17","author":"Yang","year":"2021","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.pharmr.2025.100065_bib105","doi-asserted-by":"crossref","first-page":"744","DOI":"10.3389\/fgene.2018.00744","article-title":"Long non-coding RNA in neuronal development and neurological disorders","volume":"9","author":"Li","year":"2019","journal-title":"Front Genet"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100065_bib106","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2174\/1567205016666190725130134","article-title":"Long non-coding RNA MALAT1 inhibits neuron apoptosis and neuroinflammation while stimulates neurite outgrowth and its correlation with MiR-125b mediates PTGS2, CDK5 and FOXQ1 in Alzheimer's disease","volume":"16","author":"Ma","year":"2019","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.pharmr.2025.100065_bib107","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.omtn.2017.12.011","article-title":"Long non-coding RNAs, novel culprits, or bodyguards in neurodegenerative diseases","volume":"10","author":"Wang","year":"2018","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.pharmr.2025.100065_bib108","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.853180","article-title":"The emerging roles of the \u03b2-secretase BACE1 and the long non-coding RNA BACE1-AS in human diseases: a focus on neurodegenerative diseases and cancer","volume":"14","author":"Sayad","year":"2022","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.pharmr.2025.100065_bib109","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.omtn.2020.07.005","article-title":"Targeting long non-coding RNA to therapeutically regulate gene expression in cancer","volume":"21","author":"Fu","year":"2020","journal-title":"Mol Ther Nucleic Acids"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib110","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13115","article-title":"A lncRNA survey finds increases in neuroprotective LINC-PINT in Parkinson's disease substantia nigra","volume":"19","author":"Simchovitz","year":"2020","journal-title":"Aging Cell"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib111","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/HCO.0000000000001041","article-title":"Long noncoding RNAs in cardiovascular disease","volume":"38","author":"Kohlmaier","year":"2023","journal-title":"Curr Opin Cardiol"},{"issue":"36","key":"10.1016\/j.pharmr.2025.100065_bib112","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1093\/eurheartj\/ehaa519","article-title":"Targeting muscle-enriched long non-coding RNA H19 reverses pathological cardiac hypertrophy","volume":"41","author":"Viereck","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmr.2025.100065_bib113","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.vph.2018.10.001","article-title":"Role of flow-sensitive microRNAs and long noncoding RNAs in vascular dysfunction and atherosclerosis","volume":"114","author":"Kumar","year":"2019","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.pharmr.2025.100065_bib114","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/8859677","article-title":"The role of ANRIL in atherosclerosis","volume":"2022","author":"Razeghian-Jahromi","year":"2022","journal-title":"Dis Markers"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib115","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12929-020-00647-w","article-title":"Expedition to the missing link: long noncoding RNAs in cardiovascular diseases","volume":"27","author":"Yeh","year":"2020","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.pharmr.2025.100065_bib116","doi-asserted-by":"crossref","first-page":"6779","DOI":"10.1038\/ncomms7779","article-title":"APF lncRNA regulates autophagy and myocardial infarction by targeting miR-188-3p","volume":"6","author":"Wang","year":"2015","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100065_bib117","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3892\/ijmm.2021.5042","article-title":"Long-chain non-coding RNA GAS5 promotes cell autophagy by modulating the miR-181c-5p\/ATG5 and miR-1192\/ATG12 axes","volume":"48","author":"Xu","year":"2021","journal-title":"Int J Mol Med"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100065_bib118","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41573-021-00219-z","article-title":"Noncoding RNA therapeutics\u2014challenges and potential solutions","volume":"20","author":"Winkle","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib119","first-page":"22","article-title":"MALAT1 long non-coding RNA: functional implications","volume":"6","author":"Arun","year":"2020","journal-title":"Noncoding RNA"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib120","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1021\/acsami.8b18288","article-title":"Antisense oligonucleotide-conjugated nanostructure-targeting lncRNA MALAT1 inhibits cancer metastasis","volume":"11","author":"Gong","year":"2019","journal-title":"ACS Appl Mater Interfaces"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100065_bib121","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1080\/15476286.2017.1358347","article-title":"The long noncoding RNA Malat1: its physiological and pathophysiological functions","volume":"14","author":"Zhang","year":"2017","journal-title":"RNA Biol"},{"issue":"13","key":"10.1016\/j.pharmr.2025.100065_bib122","doi-asserted-by":"crossref","first-page":"R526","DOI":"10.1016\/j.cub.2015.05.032","article-title":"Who discovered messenger RNA?","volume":"25","author":"Cobb","year":"2015","journal-title":"Curr Biol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib123","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1084\/jem.79.2.137","article-title":"Studies on the chemical nature of the substance inducing transformation of pneumococcal types: induction of transformation by a desoxyribonucleic acid fraction isolated from pneumococcus type iii","volume":"79","author":"Avery","year":"1944","journal-title":"J Exp Med"},{"issue":"4361","key":"10.1016\/j.pharmr.2025.100065_bib124","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/171964b0","article-title":"Genetical implications of the structure of deoxyribonucleic acid","volume":"171","author":"Watson","year":"1953","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib125","first-page":"207","article-title":"La localization des acides pentosenucl\u00e9iques dans les tissues animaux et les oufs d\u2019Amphibiens en voie de d\u00e9veloppement","volume":"53","author":"Brachet","year":"1942","journal-title":"Archs Biol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib126","first-page":"127","article-title":"The relations between nucleic acid and protein synthesis","author":"Caspersson","year":"1947","journal-title":"Symp Soc Exp Biol"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100065_bib127","first-page":"251","article-title":"Duplicating mechanism for peptide chain and nucleic acid synthesis","volume":"15","author":"AL","year":"1952","journal-title":"Enzymologia"},{"issue":"4377","key":"10.1016\/j.pharmr.2025.100065_bib128","doi-asserted-by":"crossref","DOI":"10.1038\/172541a0","article-title":"Nucleic acid template hypotheses","volume":"172","author":"Dounce","year":"1953","journal-title":"Nature"},{"key":"10.1016\/j.pharmr.2025.100065_bib129","first-page":"138","article-title":"On protein synthesis","volume":"12","author":"Crick","year":"1958","journal-title":"Symp Soc Exp Biol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib130","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0021-9258(19)77302-5","article-title":"A soluble ribonucleic acid intermediate in protein synthesis","volume":"231","author":"Hoagland","year":"1958","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100065_bib131","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1085\/jgp.36.6.777","article-title":"Nucleic acid economy in bacteria infected with bacteriophage T2: I. Purine and pyrimidine composition","volume":"36","author":"Hershey","year":"1953","journal-title":"J Gen Physiol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib132","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/0006-3002(58)90010-6","article-title":"Properties of ribonucleic acid turnover in T2-infected Escherichia coli","volume":"29","author":"Astrachan","year":"1958","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib133","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/0006-3002(58)90414-1","article-title":"The action of ribonuclease, thiouracil and azaguanine on the synthesis of phage proteins by an induced lysogenic bacterium","volume":"27","author":"Jeener","year":"1958","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pharmr.2025.100065_bib134","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/190576a0","article-title":"An unstable intermediate carrying information from genes to ribosomes for protein synthesis","volume":"190","author":"Brenner","year":"1961","journal-title":"Nature"},{"key":"10.1016\/j.pharmr.2025.100065_bib135","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/190581a0","article-title":"Unstable ribonucleic acid revealed by pulse labelling of Escherichia coli","volume":"190","author":"Gros","year":"1961","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib136","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0022-2836(61)80072-7","article-title":"Genetic regulatory mechanisms in the synthesis of proteins","volume":"3","author":"Jacob","year":"1961","journal-title":"J Mol Biol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib137","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1073\/pnas.47.2.137","article-title":"Sequence complementarity of T2-DNA and T2-specific RNA","volume":"47","author":"Hall","year":"1961","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmr.2025.100065_bib138","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41541-020-0159-8","article-title":"The promise of mRNA vaccines: a biotech and industrial perspective","volume":"5","author":"Jackson","year":"2020","journal-title":"NPJ Vaccines"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib139","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.bbagrm.2018.09.011","article-title":"mRNA cap regulation in mammalian cell function and fate","volume":"1862","author":"Galloway","year":"2019","journal-title":"Biochim Biophys Acta Gene Regul Mech"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib140","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nrmicro2675","article-title":"Conventional and unconventional mechanisms for capping viral mRNA","volume":"10","author":"Decroly","year":"2011","journal-title":"Nat Rev Microbiol"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100065_bib141","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41557-022-00972-7","article-title":"Photocaged 5' cap analogues for optical control of mRNA translation in cells","volume":"14","author":"Kl\u00f6cker","year":"2022","journal-title":"Nat Chem"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib142","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/wrna.52","article-title":"Cap and cap-binding proteins in the control of gene expression","volume":"2","author":"Topisirovic","year":"2011","journal-title":"Wiley Interdiscip Rev RNA"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib143","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/nrm.2017.103","article-title":"Functional 5' UTR mRNA structures in eukaryotic translation regulation and how to find them","volume":"19","author":"Leppek","year":"2018","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib144","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1038\/s41467-024-49508-2","article-title":"Optimizing 5\u2019UTRs for mRNA-delivered gene editing using deep learning","volume":"15","author":"Castillo-Hair","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib145","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1038\/s41467-021-24436-7","article-title":"High-throughput 5' UTR engineering for enhanced protein production in non-viral gene therapies","volume":"12","author":"Cao","year":"2021","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100065_bib146","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.tcb.2011.03.003","article-title":"Pre-mRNA splicing: where and when in the nucleus","volume":"21","author":"Han","year":"2011","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.pharmr.2025.100065_bib147","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2024.1371596","article-title":"Codon-optimization in gene therapy: promises, prospects and challenges","volume":"12","author":"Paremskaia","year":"2024","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.pharmr.2025.100065_bib148","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.actbio.2021.06.020","article-title":"Synthetic modified messenger RNA for therapeutic applications","volume":"131","author":"Gao","year":"2021","journal-title":"Acta Biomater"},{"key":"10.1016\/j.pharmr.2025.100065_bib149","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.omtn.2022.10.003","article-title":"Cytidine-containing tails robustly enhance and prolong protein production of synthetic mRNA in cell and in vivo","volume":"30","author":"Li","year":"2022","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1-2","key":"10.1016\/j.pharmr.2025.100065_bib150","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1089\/ten.tea.2017.0444","article-title":"Messenger RNA delivery for tissue engineering and regenerative medicine applications","volume":"25","author":"Patel","year":"2019","journal-title":"Tissue Eng Part A"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100065_bib151","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41587-022-01294-2","article-title":"The clinical progress of mRNA vaccines and immunotherapies","volume":"40","author":"Barbier","year":"2022","journal-title":"Nat Biotechnol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib152","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12943-021-01348-0","article-title":"mRNA therapeutics in cancer immunotherapy","volume":"20","author":"Beck","year":"2021","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib153","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12943-021-01329-3","article-title":"mRNA in cancer immunotherapy: beyond a source of antigen","volume":"20","author":"Van Hoecke","year":"2021","journal-title":"Mol Cancer"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100065_bib154","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1093\/jmcb\/mjz049","article-title":"POLIII-derived non-coding RNAs acting as scaffolds and decoys","volume":"11","author":"T\u00e4uber","year":"2019","journal-title":"J Mol Cell Biol"},{"issue":"4480","key":"10.1016\/j.pharmr.2025.100065_bib155","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1126\/science.6164096","article-title":"Two novel classes of small ribonucleoproteins detected by antibodies associated with lupus erythematosus","volume":"211","author":"Lerner","year":"1981","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100065_bib156","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1101\/gad.14.7.777","article-title":"Ro ribonucleoproteins contribute to the resistance of Deinococcus radiodurans to ultraviolet irradiation","volume":"14","author":"Chen","year":"2000","journal-title":"Genes Dev"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100065_bib157","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1093\/molbev\/msm084","article-title":"Ro-Associated Y RNAs in metazoans: evolution and diversification","volume":"24","author":"Perreault","year":"2007","journal-title":"Mol Biol Evol"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100065_bib158","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1017\/S1355838298971667","article-title":"Binding of the 60-kDa Ro autoantigen to Y RNAs: evidence for recognition in the major groove of a conserved helix","volume":"4","author":"Green","year":"1998","journal-title":"RNA"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100065_bib159","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1073\/pnas.94.7.3040","article-title":"The ultrastructural localization of 60-kDa Ro protein and human cytoplasmic RNAs: association with novel electron-dense bodies","volume":"94","author":"Farris","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib160","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1046\/j.1365-2249.2001.01566.x","article-title":"Heterogeneity of human Ro ribonucleoproteins (RNPS): nuclear retention of Ro RNPS containing the human hY5 RNA in human and mouse cells","volume":"125","author":"Gendron","year":"2001","journal-title":"Clin Exp Immunol"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100065_bib161","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/nrg3074","article-title":"Non-coding RNAs in human disease","volume":"12","author":"Esteller","year":"2011","journal-title":"Nat Rev Genet"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib162","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ygeno.2009.05.002","article-title":"Eukaryotic snoRNAs: a paradigm for gene expression flexibility","volume":"94","author":"Dieci","year":"2009","journal-title":"Genomics"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100065_bib163","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3390\/biology10080809","article-title":"SnoRNA in cancer progression, metastasis and immunotherapy response","volume":"10","author":"van der Werf","year":"2021","journal-title":"Biology"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib164","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41420-022-01056-8","article-title":"snoRNAs: functions and mechanisms in biological processes, and roles in tumor pathophysiology","volume":"8","author":"Huang","year":"2022","journal-title":"Cell Death Discov"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib165","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/emboj\/19.3.317","article-title":"Crystal structure of a fibrillarin homologue from Methanococcus jannaschii, a hyperthermophile, at 1.6 A resolution","volume":"19","author":"Wang","year":"2000","journal-title":"EMBO J"},{"issue":"6602","key":"10.1016\/j.pharmr.2025.100065_bib166","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/383732a0","article-title":"Targeted ribose methylation of RNA in vivo directed by tailored antisense RNA guides","volume":"383","author":"Cavaill\u00e9","year":"1996","journal-title":"Nature"},{"issue":"14","key":"10.1016\/j.pharmr.2025.100065_bib167","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1093\/emboj\/20.14.3617","article-title":"Small nucleolar RNA-guided post-transcriptional modification of cellular RNAs","volume":"20","author":"Kiss","year":"2001","journal-title":"EMBO J"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib168","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/emboj\/17.3.797","article-title":"Sequence and structural elements of methylation guide snoRNAs essential for site-specific ribose methylation of pre-rRNA","volume":"17","author":"Kiss-L\u00e1szl\u00f3","year":"1998","journal-title":"EMBO J"},{"issue":"6564","key":"10.1016\/j.pharmr.2025.100065_bib169","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/379464a0","article-title":"A mammalian gene with introns instead of exons generating stable RNA products","volume":"379","author":"Tycowski","year":"1996","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100065_bib170","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1093\/nar\/17.9.3373","article-title":"Highly efficient chemical synthesis of 2'-O-methyloligoribonucleotides and tetrabiotinylated derivatives; novel probes that are resistant to degradation by RNA or DNA specific nucleases","volume":"17","author":"Sproat","year":"1989","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.pharmr.2025.100065_bib171","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/206849","article-title":"Regulatory role of small nucleolar RNAs in human diseases","volume":"2015","author":"Stepanov","year":"2015","journal-title":"Biomed Res Int"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100065_bib172","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1002\/j.1460-2075.1989.tb08463.x","article-title":"U3, U8 and U13 comprise a new class of mammalian snRNPs localized in the cell nucleolus","volume":"8","author":"Tyc","year":"1989","journal-title":"EMBO J"},{"key":"10.1016\/j.pharmr.2025.100065_bib173","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nature08909","article-title":"Expansion of the eukaryotic proteome by alternative splicing","volume":"463","author":"Nilsen","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.pharmr.2025.100065_bib174","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gene.2004.10.022","article-title":"Function of alternative splicing","volume":"344","author":"Stamm","year":"2005","journal-title":"Gene"},{"issue":"26","key":"10.1016\/j.pharmr.2025.100065_bib175","doi-asserted-by":"crossref","first-page":"14311","DOI":"10.1073\/pnas.250426397","article-title":"Identification of brain-specific and imprinted small nucleolar RNA genes exhibiting an unusual genomic organization","volume":"97","author":"Cavaill\u00e9","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100065_bib176","doi-asserted-by":"crossref","first-page":"E1625","DOI":"10.1073\/pnas.1519292113","article-title":"Dual function of C\/D box small nucleolar RNAs in rRNA modification and alternative pre-mRNA splicing","volume":"113","author":"Falaleeva","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib177","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.molcel.2008.10.017","article-title":"A human snoRNA with microRNA-like functions","volume":"32","author":"Ender","year":"2008","journal-title":"Mol Cell"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100065_bib178","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.molmed.2024.03.004","article-title":"SnoRNAs in cardiovascular development, function, and disease","volume":"30","author":"Chabronova","year":"2024","journal-title":"Trends Mol Med"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100065_bib179","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1073\/pnas.73.11.3852","article-title":"Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures","volume":"73","author":"Sanger","year":"1976","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7441","key":"10.1016\/j.pharmr.2025.100065_bib180","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature11928","article-title":"Circular RNAs are a large class of animal RNAs with regulatory potency","volume":"495","author":"Memczak","year":"2013","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib181","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030733","article-title":"Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types","volume":"7","author":"Salzman","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100065_bib182","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.molcel.2017.10.034","article-title":"The output of protein-coding genes shifts to circular RNAs when the pre-mRNA processing machinery is limiting","volume":"68","author":"Liang","year":"2017","journal-title":"Mol Cell"},{"issue":"20","key":"10.1016\/j.pharmr.2025.100065_bib183","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1101\/gad.270421.115","article-title":"Combinatorial control of Drosophila circular RNA expression by intronic repeats, hnRNPs, and SR proteins","volume":"29","author":"Kramer","year":"2015","journal-title":"Genes Dev"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100065_bib184","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1186\/s13059-014-0409-z","article-title":"Expanded identification and characterization of mammalian circular RNAs","volume":"15","author":"Guo","year":"2014","journal-title":"Genome Biol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib185","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1261\/rna.035667.112","article-title":"Circular RNAs are abundant, conserved, and associated with ALU repeats","volume":"19","author":"Jeck","year":"2013","journal-title":"RNA"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib186","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/nar\/gkv1367","article-title":"Circular RNAs are long-lived and display only minimal early alterations in response to a growth factor","volume":"44","author":"Enuka","year":"2016","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib187","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nsmb.2959","article-title":"Exon-intron circular RNAs regulate transcription in the nucleus","volume":"22","author":"Li","year":"2015","journal-title":"Nat Struct Mol Biol"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100065_bib188","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.molcel.2013.08.017","article-title":"Circular intronic long noncoding RNAs","volume":"51","author":"Zhang","year":"2013","journal-title":"Mol Cell"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100065_bib189","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1261\/rna.043687.113","article-title":"circBase: a database for circular RNAs","volume":"20","author":"Gla\u017ear","year":"2014","journal-title":"RNA"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib190","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.cell.2018.12.021","article-title":"The landscape of circular RNA in cancer","volume":"176","author":"Vo","year":"2019","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100065_bib191","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/0092-8674(93)90279-Y","article-title":"Circular transcripts of the testis-determining gene Sry in adult mouse testis","volume":"73","author":"Capel","year":"1993","journal-title":"Cell"},{"issue":"1-2","key":"10.1016\/j.pharmr.2025.100065_bib192","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0378-1119(95)00639-7","article-title":"Inverted repeats are necessary for circularization of the mouse testis Sry transcript","volume":"167","author":"Dubin","year":"1995","journal-title":"Gene"},{"key":"10.1016\/j.pharmr.2025.100065_bib193","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nature11993","article-title":"Natural RNA circles function as efficient microRNA sponges","volume":"495","author":"Hansen","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.pharmr.2025.100065_bib194","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11215","article-title":"Circular RNA profiling reveals an abundant circHIPK3 that regulates cell growth by sponging multiple miRNAs","volume":"7","author":"Zheng","year":"2016","journal-title":"Nat Commun"},{"issue":"6357","key":"10.1016\/j.pharmr.2025.100065_bib195","article-title":"Hernandez- on and affects brain function","volume":"357","author":"Piwecka","year":"2017","journal-title":"Science"},{"issue":"2-3","key":"10.1016\/j.pharmr.2025.100065_bib196","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s002130100810","article-title":"Loss of a mammalian circular RNA locus causes miRNA deregulatiman studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies","volume":"156","author":"Braff","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100065_bib197","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/sj.mp.4001159","article-title":"Mouse genetic models for prepulse inhibition: an early review","volume":"7","author":"Geyer","year":"2002","journal-title":"Mol Psychiatry"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib198","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1083\/jcb.103.3.699","article-title":"Isolation and characterization of a novel ribonucleoprotein particle: large structures contain a single species of small RNA","volume":"103","author":"Kedersha","year":"1986","journal-title":"J Cell Biol"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100065_bib199","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1093\/molbev\/msp112","article-title":"Evolution of vault RNAs","volume":"26","author":"Stadler","year":"2009","journal-title":"Mol Biol Evol"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100065_bib200","doi-asserted-by":"crossref","first-page":"7868","DOI":"10.1016\/S0021-9258(18)53038-6","article-title":"Vault ribonucleoprotein particles from rat and bullfrog contain a related small RNA that is transcribed by RNA polymerase III","volume":"268","author":"Kickhoefer","year":"1993","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib201","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1083\/jcb.112.2.225","article-title":"Vaults. III. Vault ribonucleoprotein particles open into flower-like structures with octagonal symmetry","volume":"112","author":"Kedersha","year":"1991","journal-title":"J Cell Biol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib202","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00018-008-8364-z","article-title":"Vaults and the major vault protein: novel roles in signal pathway regulation and immunity","volume":"66","author":"Berger","year":"2009","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.pharmr.2025.100065_bib203","doi-asserted-by":"crossref","unstructured":"Stephen AG, Raval-Fernandes S, Huynh T, Torres M, Kickhoefer VA, Rome LH. Assembly of vault-like particles in insect cells expressing only the major vault protein. J Biol Chem. 276(26):23217-23220.","DOI":"10.1074\/jbc.C100226200"},{"issue":"46","key":"10.1016\/j.pharmr.2025.100065_bib204","doi-asserted-by":"crossref","first-page":"32712","DOI":"10.1074\/jbc.274.46.32712","article-title":"Vaults and telomerase share a common subunit, TEP1","volume":"274","author":"Kickhoefer","year":"1999","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib205","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1083\/jcb.152.1.157","article-title":"The Telomerase\/vault-associated protein TEP1 is required for vault RNA stability and its association with the vault particle","volume":"152","author":"Kickhoefer","year":"2001","journal-title":"J Cell Biol"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100065_bib206","article-title":"Therapeutic silencing of Bcl-2 by systemically administered siRNA nanotherapeutics inhibits tumor growth by autophagy and apoptosis and enhances the efficacy of chemotherapy in orthotopic xenograft models of ER (-) and ER (+) breast cancer","volume":"2","author":"Tekedereli","year":"2013","journal-title":"Mol Ther Nucleic Acids"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100065_bib207","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1111\/j.1582-4934.2008.00539.x","article-title":"Combination of taxol and Bcl-2 siRNA induces apoptosis in human glioblastoma cells and inhibits invasion, angiogenesis and tumour growth","volume":"13","author":"George","year":"2009","journal-title":"J Cell Mol Med"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100065_bib208","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1021\/acs.molpharmaceut.8b00227","article-title":"Simultaneous delivery of electrostatically complexed multiple gene-targeting siRNAs and an anticancer drug for synergistically enhanced treatment of prostate cancer","volume":"15","author":"Choi","year":"2018","journal-title":"Mol Pharm"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib209","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13073-015-0174-y","article-title":"RNA interference approaches for treatment of HIV-1 infection","volume":"7","author":"Bobbin","year":"2015","journal-title":"Genome Med"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100065_bib210","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/sj.cr.7290248","article-title":"RNAi, a new therapeutic strategy against viral infection","volume":"14","author":"Tan","year":"2004","journal-title":"Cell Res"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100065_bib211","article-title":"Hydrophobically modified siRNAs silence Huntingtin mRNA in primary neurons and mouse brain","volume":"4","author":"Alterman","year":"2015","journal-title":"Mol Ther Nucleic Acids"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100065_bib212","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1261\/rna.602307","article-title":"Chemical modification resolves the asymmetry of siRNA strand degradation in human blood serum","volume":"13","author":"Hoerter","year":"2007","journal-title":"RNA"},{"issue":"6956","key":"10.1016\/j.pharmr.2025.100065_bib213","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature01957","article-title":"The nuclear RNase III Drosha initiates microRNA processing","volume":"425","author":"Lee","year":"2003","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100065_bib214","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2174\/157339911797579179","article-title":"Synergy of microRNA and stem cell: a novel therapeutic approach for diabetes mellitus and cardiovascular diseases","volume":"7","author":"Tyagi","year":"2011","journal-title":"Curr Diabetes Rev"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100065_bib215","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.addr.2009.04.004","article-title":"siRNA vs. shRNA: similarities and differences","volume":"61","author":"Rao","year":"2009","journal-title":"Adv Drug Deliv Rev"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100065_bib216","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/nsmb1308","article-title":"Structural features of small RNA precursors determine Argonaute loading in Caenorhabditis elegans","volume":"14","author":"Steiner","year":"2007","journal-title":"Nat Struct Mol Biol"},{"issue":"23","key":"10.1016\/j.pharmr.2025.100065_bib217","doi-asserted-by":"crossref","first-page":"7964","DOI":"10.1073\/pnas.0800334105","article-title":"Characterization of endogenous human argonautes and their miRNA partners in RNA silencing","volume":"105","author":"Azuma-Mukai","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib218","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1357-2725(98)00128-9","article-title":"Eukaryotic initiation factor eIF2","volume":"31","author":"Kimball","year":"1999","journal-title":"Int J Biochem Cell Biol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib219","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0092-8674(86)90383-1","article-title":"Adenovirus VAI RNA antagonizes the antiviral action of interferon by preventing activation of the interferon-induced eIF-2\u03b1 kinase","volume":"45","author":"Kitajewski","year":"1986","journal-title":"Cell"},{"issue":"44","key":"10.1016\/j.pharmr.2025.100065_bib220","doi-asserted-by":"crossref","first-page":"34314","DOI":"10.1074\/jbc.M006804200","article-title":"HIV-1 TAR RNA enhances the interaction between Tat and cyclin T1","volume":"275","author":"Zhang","year":"2000","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib221","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrd1955","article-title":"Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease","volume":"5","author":"Ng","year":"2006","journal-title":"Nat Rev Drug Discov"},{"issue":"5454","key":"10.1016\/j.pharmr.2025.100065_bib222","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1126\/science.287.5454.820","article-title":"Adaptive recognition by nucleic acid aptamers","volume":"287","author":"Hermann","year":"2000","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100065_bib223","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1073\/pnas.92.6.2355","article-title":"Selection of an RNA molecule that mimics a major autoantigenic epitope of human insulin receptor","volume":"92","author":"Doudna","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"28","key":"10.1016\/j.pharmr.2025.100065_bib224","doi-asserted-by":"crossref","first-page":"8672","DOI":"10.1021\/ja034483t","article-title":"A DNA aptamer as a new target-specific chiral selector for HPLC","volume":"125","author":"Michaud","year":"2003","journal-title":"J Am Chem Soc"},{"issue":"4968","key":"10.1016\/j.pharmr.2025.100065_bib225","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1126\/science.2200121","article-title":"Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase","volume":"249","author":"Tuerk","year":"1990","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100065_bib226","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/clinchem\/45.9.1628","article-title":"Aptamers: an emerging class of molecules that rival antibodies in diagnostics","volume":"45","author":"Jayasena","year":"1999","journal-title":"Clin Chem"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100065_bib227","first-page":"502","article-title":"Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab","volume":"38","author":"Miele","year":"2004","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100065_bib228","first-page":"2096","article-title":"Phase I evaluation of humanized OKT3: toxicity and immunomodulatory effects of hOKT3\u03b34","volume":"59","author":"Richards","year":"1999","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100065_bib229","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1172\/JCI11325","article-title":"Developing aptamers into therapeutics","volume":"106","author":"White","year":"2000","journal-title":"J Clin Invest"},{"issue":"13","key":"10.1016\/j.pharmr.2025.100065_bib230","doi-asserted-by":"crossref","first-page":"8898","DOI":"10.1073\/pnas.132067399","article-title":"In vivo properties of an anti-GnRH Spiegelmer: an example of an oligonucleotide-based therapeutic substance class","volume":"99","author":"Wlotzka","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmr.2025.100065_bib231","series-title":"MicroRNA and Cancer: Methods and Protocols","first-page":"211","author":"Wang","year":"2011"},{"issue":"21","key":"10.1016\/j.pharmr.2025.100065_bib232","doi-asserted-by":"crossref","first-page":"6236","DOI":"10.1158\/0008-5472.CAN-14-0855","article-title":"A small-molecule modulator of the tumor-suppressor miR34a inhibits the growth of hepatocellular carcinoma","volume":"74","author":"Xiao","year":"2014","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100065_bib233","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1158\/0008-5472.CAN-16-2355","article-title":"Micellar delivery of miR-34a modulator rubone and paclitaxel in resistant prostate cancer","volume":"77","author":"Wen","year":"2017","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib234","first-page":"4483","article-title":"MicroRNA-34a inhibits liver cancer cell growth by reprogramming glucose metabolism","volume":"17","author":"Zhang","year":"2018","journal-title":"Mol Med Rep"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib235","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nm.2284","article-title":"The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44","volume":"17","author":"Liu","year":"2011","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100065_bib236","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1158\/1535-7163.MCT-11-0152","article-title":"Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice","volume":"10","author":"Pramanik","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100065_bib237","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/mt.2011.48","article-title":"Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice","volume":"19","author":"Trang","year":"2011","journal-title":"Mol Ther"},{"issue":"12_Supplement_2","key":"10.1016\/j.pharmr.2025.100065_bib238","doi-asserted-by":"crossref","first-page":"C43","DOI":"10.1158\/1535-7163.TARG-15-C43","article-title":"Abstract C43: Safety, tolerability, and clinical activity of MRX34, the first-in-class liposomal miR-34 mimic, in patients with advanced solid tumors","volume":"14","author":"Beg","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100065_bib239","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41416-020-0802-1","article-title":"Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours","volume":"12","author":"Hong","year":"2020","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib240","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nbt.1618","article-title":"Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model","volume":"28","author":"Ma","year":"2010","journal-title":"Nat Biotechnol"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100065_bib241","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1158\/0008-5472.CAN-10-3568","article-title":"Human glioma growth is controlled by MicroRNA-10b","volume":"71","author":"Gabriely","year":"2011","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100065_bib242","doi-asserted-by":"crossref","first-page":"6294","DOI":"10.1128\/JVI.03631-14","article-title":"Regulation of hepatitis C virus genome replication by Xrn1 and microRNA-122 binding to individual sites in the 5\u2032 untranslated region","volume":"89","author":"Thibault","year":"2015","journal-title":"J Virol"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100065_bib243","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.cell.2015.02.025","article-title":"Hepatitis C virus RNA functionally sequesters miR-122","volume":"160","author":"Luna","year":"2015","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100065_bib244","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1172\/JCI63539","article-title":"Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver","volume":"122","author":"Hsu","year":"2012","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100065_bib245","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1172\/JCI63455","article-title":"MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis","volume":"122","author":"Tsai","year":"2012","journal-title":"J Clin Invest"},{"issue":"7189","key":"10.1016\/j.pharmr.2025.100065_bib246","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/nature06783","article-title":"LNA-mediated microRNA silencing in non-human primates","volume":"452","author":"Elm\u00e9n","year":"2008","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib247","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/nar\/gkm1113","article-title":"Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver","volume":"36","author":"Elm\u00e9n","year":"2008","journal-title":"Nucleic Acids Res"},{"issue":"18","key":"10.1016\/j.pharmr.2025.100065_bib248","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa1209026","article-title":"Treatment of HCV infection by targeting microRNA","volume":"368","author":"Janssen","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib249","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/apt.13432","article-title":"Miravirsen dosing in chronic hepatitis C patients results in decreased micro RNA-122 levels without affecting other micro RNAs in plasma","volume":"43","author":"van der Ree","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib250","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1128\/AAC.04220-14","article-title":"In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122","volume":"59","author":"Ottosen","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"3731","key":"10.1016\/j.pharmr.2025.100065_bib251","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1126\/science.153.3731.64","article-title":"In vitro synthesis of an infectious mutant RNA with a normal RNA replicase","volume":"153","author":"Pace","year":"1966","journal-title":"Science"},{"key":"10.1016\/j.pharmr.2025.100065_bib252","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/s41587-022-01491-z","article-title":"Unlocking the promise of mRNA therapeutics","volume":"40","author":"Rohner","year":"2022","journal-title":"Nat Biotechnol"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100065_bib253","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.3390\/vaccines9101187","article-title":"Self-replicating RNA viruses for vaccine development against infectious diseases and cancer","volume":"9","author":"Lundstrom","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"14","key":"10.1016\/j.pharmr.2025.100065_bib254","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.3390\/ijms21145130","article-title":"Self-amplifying RNA viruses as RNA vaccines","volume":"21","author":"Lundstrom","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100065_bib255","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics--developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat Rev Drug Discov"},{"issue":"36","key":"10.1016\/j.pharmr.2025.100065_bib256","doi-asserted-by":"crossref","first-page":"14604","DOI":"10.1073\/pnas.1209367109","article-title":"Nonviral delivery of self-amplifying RNA vaccines","volume":"109","author":"Geall","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100065_bib257","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.3390\/molecules23123310","article-title":"Self-replicating RNA viruses for RNA therapeutics","volume":"23","author":"Lundstrom","year":"2018","journal-title":"Molecules"},{"issue":"21","key":"10.1016\/j.pharmr.2025.100065_bib258","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232112884","article-title":"Self-amplifying RNA approach for protein replacement therapy","volume":"23","author":"Papukashvili","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib259","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1128\/mr.58.3.491-562.1994","article-title":"The alphaviruses: gene expression, replication, and evolution","volume":"58","author":"Strauss","year":"1994","journal-title":"Microbiol Rev"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib260","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ymthe.2019.01.020","article-title":"mRNA as a transformative technology for vaccine development to control infectious diseases","volume":"27","author":"Maruggi","year":"2019","journal-title":"Mol Ther"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100065_bib261","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1089\/hum.2017.121","article-title":"Improvement of in vivo expression of genes delivered by self-amplifying RNA using vaccinia virus immune evasion proteins","volume":"28","author":"Beissert","year":"2017","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.pharmr.2025.100065_bib262","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jconrel.2021.08.029","article-title":"Polymeric and lipid nanoparticles for delivery of self-amplifying RNA vaccines","volume":"338","author":"Blakney","year":"2021","journal-title":"J Control Release"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib263","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1038\/s41467-020-17409-9","article-title":"Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice","volume":"11","author":"McKay","year":"2020","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib264","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.nano.2015.11.001","article-title":"Polyethylenimine-based polyplex delivery of self-replicating RNA vaccines","volume":"12","author":"D\u00e9moulins","year":"2016","journal-title":"Nanomedicine"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib265","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","article-title":"Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses","volume":"26","author":"Vogel","year":"2018","journal-title":"Mol Ther"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib266","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3390\/vaccines9020097","article-title":"An update on self-amplifying mRNA vaccine development","volume":"9","author":"Blakney","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"29","key":"10.1016\/j.pharmr.2025.100065_bib267","doi-asserted-by":"crossref","first-page":"E4133","DOI":"10.1073\/pnas.1600299113","article-title":"Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose","volume":"113","author":"Chahal","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"25","key":"10.1016\/j.pharmr.2025.100065_bib268","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1056\/NEJMcibr2009737","article-title":"Amplifying RNA vaccine development","volume":"382","author":"Fuller","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib269","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1600-065X.2011.01048.x","article-title":"Recognition of nucleic acids by pattern-recognition receptors and its relevance in autoimmunity","volume":"243","author":"Kawasaki","year":"2011","journal-title":"Immunol Rev"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib270","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ymthe.2018.12.011","article-title":"Improving mRNA-based therapeutic gene delivery by expression-augmenting 3' UTRs identified by cellular library screening","volume":"27","author":"Orlandini von Niessen","year":"2019","journal-title":"Mol Ther"},{"issue":"24","key":"10.1016\/j.pharmr.2025.100065_bib271","doi-asserted-by":"crossref","first-page":"13910","DOI":"10.1073\/pnas.96.24.13910","article-title":"Mutation rates among RNA viruses","volume":"96","author":"Drake","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100065_bib272","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1073\/pnas.95.6.3152","article-title":"Rabies virus quasispecies: implications for pathogenesis","volume":"95","author":"Morimoto","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7074","key":"10.1016\/j.pharmr.2025.100065_bib273","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nature04388","article-title":"Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population","volume":"439","author":"Vignuzzi","year":"2006","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100065_bib274","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1038\/s41564-024-01655-4","article-title":"Targeted accurate RNA consensus sequencing (tARC-seq) reveals mechanisms of replication error affecting SARS-CoV-2 divergence","volume":"9","author":"Bradley","year":"2024","journal-title":"Nat Microbiol"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100065_bib275","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2106379119","article-title":"Structure and dynamics of SARS-CoV-2 proofreading exoribonuclease ExoN","volume":"119","author":"Moeller","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7675","key":"10.1016\/j.pharmr.2025.100065_bib276","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/nature24049","article-title":"RNA targeting with CRISPR-Cas13","volume":"550","author":"Abudayyeh","year":"2017","journal-title":"Nature"},{"issue":"40","key":"10.1016\/j.pharmr.2025.100065_bib277","doi-asserted-by":"crossref","first-page":"8384","DOI":"10.2174\/0929867328666210204205726","article-title":"Targeting viral RNA-dependent RNA polymerases as an antiviral therapy","volume":"28","author":"Miranda","year":"2021","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.pharmr.2025.100065_bib278","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41593-022-01207-1","article-title":"An RNA-targeting CRISPR-Cas13d system alleviates disease-related phenotypes in Huntington's disease models","volume":"26","author":"Morelli","year":"2023","journal-title":"Nat Neurosci"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib279","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.molcel.2018.09.018","article-title":"CRISPR-based technologies: impact of RNA-targeting systems","volume":"72","author":"Terns","year":"2018","journal-title":"Mol Cell"},{"key":"10.1016\/j.pharmr.2025.100065_bib280","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.120681","article-title":"Treatment of ischemic neuronal death by introducing brain-derived neurotrophic factor mRNA using polyplex nanomicelle","volume":"270","author":"Fukushima","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.pharmr.2025.100065_bib281","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.omtn.2019.02.012","article-title":"Treatment of intervertebral disk disease by the administration of mRNA encoding a cartilage-anabolic transcription factor","volume":"16","author":"Lin","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib282","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41467-021-20903-3","article-title":"Murine liver repair via transient activation of regenerative pathways in hepatocytes using lipid nanoparticle-complexed nucleoside-modified mRNA","volume":"12","author":"Rizvi","year":"2021","journal-title":"Nat Commun"},{"issue":"17","key":"10.1016\/j.pharmr.2025.100065_bib283","doi-asserted-by":"crossref","first-page":"4695","DOI":"10.1093\/nar\/19.17.4695","article-title":"Association of antisense oligonucleotides with lipoproteins prolongs the plasma half-life and modifies the tissue distribution","volume":"19","author":"de Smidt","year":"1991","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100065_bib284","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1182\/blood.V81.12.3271.3271","article-title":"In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits","volume":"81","author":"Griffin","year":"1993","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.pharmr.2025.100065_bib285","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232113460","article-title":"Improving stability and specificity of CRISPR\/Cas9 system by selective modification of guide RNAs with 2'-fluoro and locked nucleic acid nucleotides","volume":"23","author":"Sakovina","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"18","key":"10.1016\/j.pharmr.2025.100065_bib286","doi-asserted-by":"crossref","first-page":"5556","DOI":"10.1021\/jp4016068","article-title":"Structures, dynamics, and stabilities of fully modified locked nucleic acid (\u03b2-D-LNA and \u03b1-L-LNA) duplexes in comparison to pure DNA and RNA duplexes","volume":"117","author":"Suresh","year":"2013","journal-title":"J Phys Chem B"},{"issue":"13","key":"10.1016\/j.pharmr.2025.100065_bib287","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0040-4039(00)90656-7","article-title":"A dinucleoside phosphorothioate","volume":"8","author":"Eckstein","year":"1967","journal-title":"Tetrahedron Lett"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100065_bib288","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nchembio.2007.39","article-title":"Phosphorothioation of DNA in bacteria by dnd genes","volume":"3","author":"Wang","year":"2007","journal-title":"Nat Chem Biol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib289","doi-asserted-by":"crossref","first-page":"6382","DOI":"10.1038\/s41467-021-26636-7","article-title":"The origin and impeded dissemination of the DNA phosphorothioation system in prokaryotes","volume":"12","author":"Jian","year":"2021","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100065_bib290","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1021\/acschembio.0c00163","article-title":"RNA phosphorothioate modification in prokaryotes and eukaryotes","volume":"15","author":"Wu","year":"2020","journal-title":"ACS Chem Biol"},{"issue":"44","key":"10.1016\/j.pharmr.2025.100065_bib291","doi-asserted-by":"crossref","first-page":"23885","DOI":"10.1002\/anie.202106215","article-title":"Strategies to avoid artifacts in mass spectrometry-based epitranscriptome analyses","volume":"60","author":"Kaiser","year":"2021","journal-title":"Angew Chem Int Ed Engl"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100065_bib292","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1089\/nat.2014.0506","article-title":"essential components of therapeutic oligonucleotides","volume":"24","author":"Eckstein F.","year":"2014","journal-title":"Nucleic Acid Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib293","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1089\/oli.1.1997.7.43","article-title":"Stability of stereoregular oligo (nucleoside phosphorothioate)s in human plasma: diastereoselectivity of plasma 3\u2035-exonuclease","volume":"7","author":"Kozio\u0142kiewicz","year":"1997","journal-title":"Antisense Nucleic Acid Drug Dev"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100065_bib294","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1093\/nar\/16.8.3209","article-title":"Physicochemical properties of phospborothioate oligodeoxynucleotides","volume":"16","author":"Stein","year":"1988","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib295","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1006\/jmbi.1997.1586","article-title":"Structural principles for the inhibition of the 3\u2032-5\u2032 exonuclease activity of Escherichia coli DNA polymerase I by phosphorothioates","volume":"277","author":"Brautigam","year":"1998","journal-title":"J Mol Biol"},{"issue":"22","key":"10.1016\/j.pharmr.2025.100065_bib296","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1093\/nar\/25.22.4429","article-title":"The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA:RNA duplexes","volume":"25","author":"Freier","year":"1997","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100065_bib297","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/nar\/gkad067","article-title":"Chemistry, structure and function of approved oligonucleotide therapeutics","volume":"51","author":"Egli","year":"2023","journal-title":"Nucleic Acids Res"},{"issue":"19","key":"10.1016\/j.pharmr.2025.100065_bib298","doi-asserted-by":"crossref","first-page":"7079","DOI":"10.1073\/pnas.85.19.7079","article-title":"Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus","volume":"85","author":"Agrawal","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmr.2025.100065_bib299","first-page":"143","article-title":"An improved method for the synthesis and deprotection of methylphosphonate oligonucleotides","volume":"20","author":"Hogrefe","year":"1993","journal-title":"Methods Mol Biol"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib300","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1517\/17425250902877680","article-title":"Antisense oligonucleotide pharmacokinetics and metabolism","volume":"5","author":"Geary","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.pharmr.2025.100065_bib301","first-page":"127","author":"Crooke","year":"2002"},{"key":"10.1016\/j.pharmr.2025.100065_bib302","series-title":"Gene and Cell Therapy, Templeton NS, ed.","first-page":"497","author":"Bennett","year":"2009"},{"issue":"43","key":"10.1016\/j.pharmr.2025.100065_bib303","doi-asserted-by":"crossref","first-page":"26801","DOI":"10.1016\/S0021-9258(18)47090-1","article-title":"Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding","volume":"269","author":"Brown","year":"1994","journal-title":"J Biol Chem"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100065_bib304","doi-asserted-by":"crossref","first-page":"7819","DOI":"10.1093\/nar\/gku484","article-title":"TCP1 complex proteins interact with phosphorothioate oligonucleotides and can co-localize in oligonucleotide-induced nuclear bodies in mammalian cells","volume":"42","author":"Liang","year":"2014","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100065_bib305","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1093\/nar\/gkv143","article-title":"Identification and characterization of intracellular proteins that bind oligonucleotides with phosphorothioate linkages","volume":"43","author":"Liang","year":"2015","journal-title":"Nucleic Acids Res"},{"issue":"13","key":"10.1016\/j.pharmr.2025.100065_bib306","doi-asserted-by":"crossref","first-page":"8648","DOI":"10.1093\/nar\/gku579","article-title":"Phosphorothioate oligonucleotides can displace NEAT1 RNA and form nuclear paraspeckle-like structures","volume":"42","author":"Shen","year":"2014","journal-title":"Nucleic Acids Res"},{"issue":"2-3","key":"10.1016\/j.pharmr.2025.100065_bib307","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/0014-5793(95)00517-D","article-title":"Phosphorothioate oligonucleotides bind in a non sequence-specific manner to the nucleolar protein C23\/nucleolin","volume":"366","author":"Weidner","year":"1995","journal-title":"FEBS Lett"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib308","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkp841","article-title":"Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents","volume":"38","author":"Stein","year":"2009","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100065_bib309","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.1093\/nar\/gkr089","article-title":"Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes","volume":"39","author":"Koller","year":"2011","journal-title":"Nucleic Acids Res"},{"issue":"26","key":"10.1016\/j.pharmr.2025.100065_bib310","doi-asserted-by":"crossref","first-page":"7967","DOI":"10.1021\/bi0343774","article-title":"RNA interference in mammalian cells by chemically-modified RNA","volume":"42","author":"Braasch","year":"2003","journal-title":"Biochemistry"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib311","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1084\/jem.20140391","article-title":"Phosphorothioate backbone modifications of nucleotide-based drugs are potent platelet activators","volume":"212","author":"Flierl","year":"2015","journal-title":"J Exp Med"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100065_bib312","first-page":"1444","article-title":"Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors?","volume":"2","author":"Henry","year":"2001","journal-title":"Curr Opin Investig Drugs"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib313","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/nar\/gkg147","article-title":"Tolerance for mutations and chemical modifications in a siRNA","volume":"31","author":"Amarzguioui","year":"2003","journal-title":"Nucleic Acids Res"},{"issue":"20","key":"10.1016\/j.pharmr.2025.100065_bib314","doi-asserted-by":"crossref","first-page":"5991","DOI":"10.1093\/nar\/gkh936","article-title":"RNA interference using boranophosphate siRNAs: structure-activity relationships","volume":"32","author":"Hall","year":"2004","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100065_bib315","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1261\/rna.5103703","article-title":"siRNA function in RNAi: a chemical modification analysis","volume":"9","author":"Chiu","year":"2003","journal-title":"RNA"},{"issue":"39","key":"10.1016\/j.pharmr.2025.100065_bib316","doi-asserted-by":"crossref","first-page":"9147","DOI":"10.1021\/acs.jpcb.8b07687","article-title":"Structural and energetic effects of O2\u2032-ribose methylation of protonated purine nucleosides","volume":"122","author":"He","year":"2018","journal-title":"J Phys Chem B"},{"key":"10.1016\/j.pharmr.2025.100065_bib317","series-title":"The Excitement of Discovery: Selected Papers of Alexander Rich: A Tribute to Alexander Rich","author":"Zhang","year":"2019"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100065_bib318","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1042\/BCJ20180445","article-title":"The chemical diversity of RNA modifications","volume":"476","author":"Ontiveros","year":"2019","journal-title":"Biochem J"},{"issue":"15","key":"10.1016\/j.pharmr.2025.100065_bib319","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1021\/jm800219f","article-title":"The many roles for fluorine in medicinal chemistry","volume":"51","author":"Hagmann","year":"2008","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib320","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1039\/B610213C","article-title":"Fluorine in medicinal chemistry","volume":"37","author":"Purser","year":"2008","journal-title":"Chem Soc Rev"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100065_bib321","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1021\/jm00059a007","article-title":"Uniformly modified 2'-deoxy-2'-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets","volume":"36","author":"Kawasaki","year":"1993","journal-title":"J Med Chem"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100065_bib322","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1093\/nar\/gkq1270","article-title":"Unexpected origins of the enhanced pairing affinity of 2'-fluoro-modified RNA","volume":"39","author":"Pallan","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.pharmr.2025.100065_bib323","first-page":"212","article-title":"New twists on nucleic acids. Carbohydrate modifications in antisense research","volume":"580","author":"Griffey","year":"1994","journal-title":"Am Chem Soc"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100065_bib324","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1093\/nar\/gkg393","article-title":"Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells","volume":"31","author":"Czauderna","year":"2003","journal-title":"Nucleic Acids Res"},{"issue":"23","key":"10.1016\/j.pharmr.2025.100065_bib325","doi-asserted-by":"crossref","first-page":"6877","DOI":"10.1093\/emboj\/20.23.6877","article-title":"Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate","volume":"20","author":"Elbashir","year":"2001","journal-title":"EMBO J"},{"issue":"5801","key":"10.1016\/j.pharmr.2025.100065_bib326","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1126\/science.1132505","article-title":"5'-Triphosphate RNA is the ligand for RIG-I","volume":"314","author":"Hornung","year":"2006","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib327","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/108729003321629638","article-title":"Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing","volume":"13","author":"Harborth","year":"2003","journal-title":"Antisense Nucleic Acid Drug Dev"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100065_bib328","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nchembio.939","article-title":"Synthetic oligonucleotides recruit ILF2\/3 to RNA transcripts to modulate splicing","volume":"8","author":"Rigo","year":"2012","journal-title":"Nat Chem Biol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib329","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.clinthera.2006.01.009","article-title":"Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: a review","volume":"28","author":"Kourlas","year":"2006","journal-title":"Clin Ther"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100065_bib330","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1002\/anie.201006519","article-title":"Unique gene-silencing and structural properties of 2'-fluoro-modified siRNAs","volume":"50","author":"Manoharan","year":"2011","journal-title":"Angew Chem Int Ed Engl"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100065_bib331","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","article-title":"The current state and future directions of RNAi-based therapeutics","volume":"18","author":"Setten","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.pharmr.2025.100065_bib332","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3389\/fimmu.2014.00461","article-title":"Toll-like receptor signaling pathways","volume":"5","author":"Kawasaki","year":"2014","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100065_bib333","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S1097-2765(00)00106-4","article-title":"Functional anatomy of a dsRNA trigger: differential requirement for the two trigger strands in RNA interference","volume":"6","author":"Parrish","year":"2000","journal-title":"Mol Cell"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100065_bib334","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1093\/nar\/gkn042","article-title":"Functional dissection of siRNA sequence by systematic DNA substitution: modified siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with significantly reduced off-target effect","volume":"36","author":"Ui-Tei","year":"2008","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100065_bib335","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1261\/rna.5239604","article-title":"In vivo activity of nuclease-resistant siRNAs","volume":"10","author":"Layzer","year":"2004","journal-title":"RNA"},{"issue":"13","key":"10.1016\/j.pharmr.2025.100065_bib336","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1021\/jm050044o","article-title":"Positional effect of chemical modifications on short interference RNA activity in mammalian cells","volume":"48","author":"Prakash","year":"2005","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib337","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1084\/jem.20111075","article-title":"The 2\u2032-O-methylation status of a single guanosine controls transfer RNA\u2013mediated Toll-like receptor 7 activation or inhibition","volume":"209","author":"J\u00f6ckel","year":"2012","journal-title":"J Exp Med"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100065_bib338","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1261\/rna.30706","article-title":"Position-specific chemical modification of siRNAs reduces \"off-target\" transcript silencing","volume":"12","author":"Jackson","year":"2006","journal-title":"RNA"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib339","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrd3625","article-title":"RNA therapeutics: beyond RNA interference and antisense oligonucleotides","volume":"11","author":"Kole","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100065_bib340","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1093\/nar\/15.11.4403","article-title":"Site-directed cleavage of RNA","volume":"15","author":"Shibahara","year":"1987","journal-title":"Nucleic Acids Res"},{"issue":"19","key":"10.1016\/j.pharmr.2025.100065_bib341","doi-asserted-by":"crossref","first-page":"14514","DOI":"10.1016\/S0021-9258(19)85268-7","article-title":"Evaluation of 2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression","volume":"268","author":"Monia","year":"1993","journal-title":"J Biol Chem"},{"issue":"6836","key":"10.1016\/j.pharmr.2025.100065_bib342","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/35078107","article-title":"Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells","volume":"411","author":"Elbashir","year":"2001","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib343","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.bbrc.2006.02.049","article-title":"Chemical modification of siRNAs to improve serum stability without loss of efficacy","volume":"342","author":"Choung","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib344","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1261\/rna.2150806","article-title":"Small interfering RNAs containing full 2\u2032-O-methylribonucleotide-modified sense strands display Argonaute2\/eIF2C2-dependent activity","volume":"12","author":"Kraynack","year":"2006","journal-title":"RNA"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib345","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1021\/jm049167j","article-title":"Fully 2'-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA","volume":"48","author":"Allerson","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmr.2025.100065_bib346","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/hlca.19950780219","article-title":"A new access to 2\u2032-O-alkylated ribonucleosides and properties of 2\u2032-O- alkylated oligoribonucleotides","volume":"78","author":"Martin","year":"1995","journal-title":"Helv Chim Acta"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib347","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/hlca.19950780219","article-title":"Ein neuer Zugang zu 2\u2032-O-alkylribonucleosiden und eigenschaften deren oligonucleotide","volume":"78","author":"Martin","year":"1995","journal-title":"Helv Chim Acta"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib348","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/(SICI)1097-0282(1998)48:4<234::AID-BIP4>3.0.CO;2-H","article-title":"X-ray crystallographic analysis of the hydration of A- and B-form DNA at atomic resolution","volume":"48","author":"Egli","year":"1998","journal-title":"Biopolymers"},{"issue":"30","key":"10.1016\/j.pharmr.2025.100065_bib349","doi-asserted-by":"crossref","first-page":"10626","DOI":"10.1021\/bi980392a","article-title":"Correlating structure and stability of DNA duplexes with incorporated 2 \u2018-O-modified RNA analogues","volume":"37","author":"Tereshko","year":"1998","journal-title":"Biochemistry"},{"key":"10.1016\/j.pharmr.2025.100065_bib350","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1093\/nar\/gnh044","article-title":"siRNA relieves chronic neuropathic pain","volume":"32","author":"Dorn","year":"2004","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib351","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nm1191","article-title":"Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7","volume":"11","author":"Hornung","year":"2005","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib352","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/nar\/gki193","article-title":"Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality","volume":"33","author":"Elm\u00e9n","year":"2005","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib353","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1158\/1535-7163.MCT-06-0195","article-title":"Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo","volume":"6","author":"Mook","year":"2007","journal-title":"Mol Cancer Ther"},{"issue":"14","key":"10.1016\/j.pharmr.2025.100065_bib354","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1016\/S0040-4020(98)00094-5","article-title":"LNA (Locked Nucleic Acids): synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition","volume":"54","author":"Koshkin","year":"1998","journal-title":"Tetrahedron"},{"issue":"50","key":"10.1016\/j.pharmr.2025.100065_bib355","doi-asserted-by":"crossref","first-page":"8735","DOI":"10.1016\/S0040-4039(97)10322-7","article-title":"Synthesis of 2\u2032-O, 4\u2032-C-methyleneuridine and-cytidine. Novel bicyclic nucleosides having a fixed C3,-endo sugar puckering","volume":"38","author":"Obika","year":"1997","journal-title":"Tetrahedron Lett"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100065_bib356","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1093\/nar\/30.9.1911","article-title":"Design of antisense oligonucleotides stabilized by locked nucleic acids","volume":"30","author":"Kurreck","year":"2002","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib357","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1074-5521(00)00058-2","article-title":"Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA","volume":"8","author":"Braasch","year":"2001","journal-title":"Chem Biol"},{"issue":"30","key":"10.1016\/j.pharmr.2025.100065_bib358","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1016\/S0040-4039(98)01084-3","article-title":"Stability and structural features of the duplexes containing nucleoside analogues with a fixed N-type conformation, 2\u2032-O, 4\u2032-C-methyleneribonucleosides","volume":"39","author":"Obika","year":"1998","journal-title":"Tetrahedron Lett"},{"issue":"15","key":"10.1016\/j.pharmr.2025.100065_bib359","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1002\/1521-3765(20000804)6:15<2687::AID-CHEM2687>3.0.CO;2-U","article-title":"Structural studies of LNA: RNA duplexes by NMR: conformations and implications for RNase H activity","volume":"6","author":"Bondensgaard","year":"2000","journal-title":"Chemistry"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib360","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1021\/ar980051p","article-title":"Synthesis of 3 \u2018-C-and 4 \u2018-C-branched oligodeoxynucleotides and the development of locked nucleic acid (LNA)","volume":"32","author":"Wengel","year":"1999","journal-title":"Acc Chem Res"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib361","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/nar\/gki193","article-title":"Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality","volume":"33","author":"Elm\u00e9n","year":"2005","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100065_bib362","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/mt.2009.91","article-title":"The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice","volume":"17","author":"Gao","year":"2009","journal-title":"Mol Ther"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib363","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1158\/1535-7163.MCT-06-0195","article-title":"Evaluation of locked nucleic acid\u2013modified small interfering RNA in vitro and in vivo","volume":"6","author":"Mook","year":"2007","journal-title":"Mol Cancer Ther"},{"issue":"16","key":"10.1016\/j.pharmr.2025.100065_bib364","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1016\/S0960-894X(98)00366-7","article-title":"The first analogues of LNA (locked nucleic acids): phosphorothioate-LNA and 2'-thio-LNA","volume":"8","author":"Kumar","year":"1998","journal-title":"Bioorg Med Chem Lett"},{"issue":"26","key":"10.1016\/j.pharmr.2025.100065_bib365","doi-asserted-by":"crossref","first-page":"8362","DOI":"10.1021\/ja071106y","article-title":"Five- and six-membered conformationally locked 2',4'-carbocyclic ribo-thymidines: synthesis, structure, and biochemical studies","volume":"129","author":"Srivastava","year":"2007","journal-title":"J Am Chem Soc"},{"issue":"19","key":"10.1016\/j.pharmr.2025.100065_bib366","doi-asserted-by":"crossref","first-page":"6729","DOI":"10.1093\/nar\/gkq505","article-title":"The crystal structure of an 'All Locked' nucleic acid duplex","volume":"38","author":"Eichert","year":"2010","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib367","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkp841","article-title":"Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents","volume":"38","author":"Stein","year":"2010","journal-title":"Nucleic Acids Res"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100065_bib368","doi-asserted-by":"crossref","first-page":"5633","DOI":"10.1073\/pnas.97.10.5633","article-title":"Potent and nontoxic antisense oligonucleotides containing locked nucleic acids","volume":"97","author":"Wahlestedt","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib369","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/nar\/gkl1071","article-title":"Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals","volume":"35","author":"Swayze","year":"2007","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.pharmr.2025.100065_bib370","series-title":"Nucleic Acids Symposium Series","article-title":"Synthesis and properties of 2\u2032, 4\u2032-BNANC, a second generation BNA","author":"Rahman","year":"2005"},{"issue":"10-12","key":"10.1016\/j.pharmr.2025.100065_bib371","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1080\/15257770701548980","article-title":"2\u2032,4\u2032-BNA NC: a novel bridged nucleic acid analogue with excellent hybridizing and nuclease resistance profiles","volume":"26","author":"Rahman","year":"2007","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100065_bib372","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1038\/mtna.2012.16","article-title":"Cholesterol-lowering action of BNA-based antisense oligonucleotides targeting PCSK9 in atherogenic diet-induced hypercholesterolemic mice","volume":"1","author":"Yamamoto","year":"2012","journal-title":"Mol Ther Nucleic Acids"},{"issue":"15","key":"10.1016\/j.pharmr.2025.100065_bib373","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1016\/j.bmc.2009.06.045","article-title":"UNA (unlocked nucleic acid): a flexible RNA mimic that allows engineering of nucleic acid duplex stability","volume":"17","author":"Langkj\u00e6r","year":"2009","journal-title":"Bioorg Med Chem"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib374","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0014-5793(88)80048-6","article-title":"A route to 2\u2032,5\u2032-oligoadenylates with increased stability towards phosphodiesterases","volume":"236","author":"Itkes","year":"1988","journal-title":"FEBS Lett"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100065_bib375","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1093\/nar\/gkp106","article-title":"A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity","volume":"37","author":"Bramsen","year":"2009","journal-title":"Nucleic Acids Res"},{"issue":"17","key":"10.1016\/j.pharmr.2025.100065_bib376","doi-asserted-by":"crossref","first-page":"5761","DOI":"10.1093\/nar\/gkq341","article-title":"A screen of chemical modifications identifies position-specific modification by UNA to most potently reduce siRNA off-target effects","volume":"38","author":"Bramsen","year":"2010","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100065_bib377","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1021\/jm050822c","article-title":"Improving RNA interference in mammalian cells by 4'-thio-modified small interfering RNA (siRNA): effect on siRNA activity and nuclease stability when used in combination with 2\u2018-O-alkyl modifications","volume":"49","author":"Dande","year":"2006","journal-title":"J Med Chem"},{"issue":"14","key":"10.1016\/j.pharmr.2025.100065_bib378","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1016\/j.febslet.2005.04.073","article-title":"RNA interference induced by siRNAs modified with 4\u2032-thioribonucleosides in cultured mammalian cells","volume":"579","author":"Hoshika","year":"2005","journal-title":"FEBS Lett"},{"key":"10.1016\/j.pharmr.2025.100065_bib379","first-page":"203","article-title":"4\u2032-Thio-2\u2032-deoxyribonucleosides: their chemistry and biological properties - a review","volume":"198","author":"Walker","year":"1997","journal-title":"Spec Publ R Soc Chem"},{"issue":"27","key":"10.1016\/j.pharmr.2025.100065_bib380","doi-asserted-by":"crossref","first-page":"8578","DOI":"10.1021\/ja802205u","article-title":"Synthesis and biophysical characterization of oligonucleotides containing a 4\u2032-selenonucleotide","volume":"130","author":"Watts","year":"2008","journal-title":"J Am Chem Soc"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib381","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-38698-2","article-title":"Convergent synthesis of phosphorodiamidate morpholino oligonucleotides (PMOs) by the H-phosphonate approach","volume":"13","author":"Tsurusaki","year":"2023","journal-title":"Sci Rep"},{"issue":"4-5","key":"10.1016\/j.pharmr.2025.100065_bib382","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.addr.2007.09.002","article-title":"Cell penetrating peptide conjugates of steric block oligonucleotides","volume":"60","author":"Lebleu","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"issue":"9791","key":"10.1016\/j.pharmr.2025.100065_bib383","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(11)60756-3","article-title":"Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study","volume":"378","author":"Cirak","year":"2011","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.pharmr.2025.100065_bib384","doi-asserted-by":"crossref","first-page":"e2270","DOI":"10.1212\/WNL.0000000000009233","article-title":"Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy","volume":"94","author":"Frank","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.pharmr.2025.100065_bib385","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jbiotec.2017.07.026","article-title":"Peptide nucleic acids: advanced tools for biomedical applications","volume":"259","author":"Gupta","year":"2017","journal-title":"J Biotechnol"},{"issue":"5037","key":"10.1016\/j.pharmr.2025.100065_bib386","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1962210","article-title":"Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide","volume":"254","author":"Nielsen","year":"1991","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100065_bib387","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1093\/nar\/21.9.2103","article-title":"Sequence selective double strand DNA cleavage by peptide nucleic acid (PNA) targeting using nuclease S1","volume":"21","author":"Demidov","year":"1993","journal-title":"Nucleic Acids Res"},{"issue":"16","key":"10.1016\/j.pharmr.2025.100065_bib388","doi-asserted-by":"crossref","first-page":"5072","DOI":"10.1021\/bi9627525","article-title":"Kinetics for hybridization of peptide nucleic acids (PNA) with DNA and RNA studied with the BIAcore technique","volume":"36","author":"Jensen","year":"1997","journal-title":"Biochemistry"},{"issue":"1-2","key":"10.1016\/j.pharmr.2025.100065_bib389","first-page":"89","article-title":"An introduction to peptide nucleic acid","volume":"1","author":"Nielsen","year":"1999","journal-title":"Curr Issues Mol Biol"},{"issue":"21","key":"10.1016\/j.pharmr.2025.100065_bib390","doi-asserted-by":"crossref","first-page":"5004","DOI":"10.1093\/nar\/26.21.5004","article-title":"A formula for thermal stability (T m) prediction of PNA\/DNA duplexes","volume":"26","author":"Giesen","year":"1998","journal-title":"Nucleic Acids Res"},{"issue":"22","key":"10.1016\/j.pharmr.2025.100065_bib391","doi-asserted-by":"crossref","first-page":"13228","DOI":"10.1074\/jbc.271.22.13228","article-title":"Invasion of the CAG triplet repeats by a complementary peptide nucleic acid inhibits transcription of the androgen receptor and TATA-binding protein genes and correlates with refolding of an active nucleosome containing a unique AR gene sequence","volume":"271","author":"Boffa","year":"1996","journal-title":"J Biol Chem"},{"issue":"46","key":"10.1016\/j.pharmr.2025.100065_bib392","doi-asserted-by":"crossref","first-page":"33114","DOI":"10.1074\/jbc.274.46.33114","article-title":"Interaction of the human NF-\u03baB p52 transcription factor with DNA-PNA hybrids mimicking the NF-\u03baB binding sites of the human immunodeficiency virus type 1 promoter","volume":"274","author":"Mischiati","year":"1999","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib393","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1093\/nar\/24.3.494","article-title":"Antisense properties of duplex-and triplex-forming PNAs","volume":"24","author":"Knudsen","year":"1996","journal-title":"Nucleic Acids Res"},{"issue":"7299","key":"10.1016\/j.pharmr.2025.100065_bib394","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/nature09039","article-title":"Structural basis for 5'-nucleotide base-specific recognition of guide RNA by human AGO2","volume":"465","author":"Frank","year":"2010","journal-title":"Nature"},{"issue":"6084","key":"10.1016\/j.pharmr.2025.100065_bib395","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1126\/science.1221551","article-title":"The crystal structure of human Argonaute2","volume":"336","author":"Schirle","year":"2012","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100065_bib396","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.3390\/molecules24122211","article-title":"Current aspects of siRNA bioconjugate for in vitro and in vivo delivery","volume":"24","author":"Tai","year":"2019","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib397","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1097-2765(02)00651-2","article-title":"Evidence that siRNAs function as guides, not primers, in the Drosophila and human RNAi pathways","volume":"10","author":"Schwarz","year":"2002","journal-title":"Mol Cell"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100065_bib398","article-title":"Silencing myostatin using cholesterol-conjugated siRNAs induces muscle growth","volume":"5","author":"Khan","year":"2016","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.pharmr.2025.100065_bib399","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nature03121","article-title":"Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs","volume":"432","author":"Soutschek","year":"2004","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100065_bib400","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/nbt1339","article-title":"Mechanisms and optimization of in vivo delivery of lipophilic siRNAs","volume":"25","author":"Wolfrum","year":"2007","journal-title":"Nat Biotechnol"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib401","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/mt.2008.14","article-title":"Efficient in vivo delivery of siRNA to the liver by conjugation of \u03b1-tocopherol","volume":"16","author":"Nishina","year":"2008","journal-title":"Mol Ther"},{"issue":"49","key":"10.1016\/j.pharmr.2025.100065_bib402","doi-asserted-by":"crossref","first-page":"16958","DOI":"10.1021\/ja505986a","article-title":"Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing","volume":"136","author":"Nair","year":"2014","journal-title":"J Am Chem Soc"},{"issue":"13","key":"10.1016\/j.pharmr.2025.100065_bib403","doi-asserted-by":"crossref","first-page":"8796","DOI":"10.1093\/nar\/gku531","article-title":"Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice","volume":"42","author":"Prakash","year":"2014","journal-title":"Nucleic Acids Res"},{"issue":"43","key":"10.1016\/j.pharmr.2025.100065_bib404","doi-asserted-by":"crossref","first-page":"10009","DOI":"10.1021\/bi00495a001","article-title":"The asialoglycoprotein receptor: a model for endocytic transport receptors","volume":"29","author":"Spiess","year":"1990","journal-title":"Biochemistry"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib405","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/nat.2018.0736","article-title":"GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics","volume":"28","author":"Springer","year":"2018","journal-title":"Nucleic Acid Ther"},{"issue":"21","key":"10.1016\/j.pharmr.2025.100065_bib406","doi-asserted-by":"crossref","first-page":"12388","DOI":"10.1093\/nar\/gkx960","article-title":"Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes","volume":"45","author":"Tanowitz","year":"2017","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib407","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1097-2765(02)00652-4","article-title":"RNAi in human cells: basic structural and functional features of small interfering RNA","volume":"10","author":"Chiu","year":"2002","journal-title":"Mol Cell"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100065_bib408","article-title":"Docosahexaenoic acid conjugation enhances distribution and safety of siRNA upon local administration in mouse brain","volume":"5","author":"Nikan","year":"2016","journal-title":"Mol Ther Nucleic Acids"},{"issue":"17","key":"10.1016\/j.pharmr.2025.100065_bib409","doi-asserted-by":"crossref","first-page":"5886","DOI":"10.1093\/nar\/gkm548","article-title":"Improved silencing properties using small internally segmented interfering RNAs","volume":"35","author":"Bramsen","year":"2007","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib410","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4161\/adna.1.1.12204","article-title":"In vivo efficacy and off-target effects of locked nucleic acid (LNA) and unlocked nucleic acid (UNA) modified siRNA and small internally segmented interfering RNA (sisiRNA) in mice bearing human tumor xenografts","volume":"1","author":"Mook","year":"2010","journal-title":"Artif DNA PNA XNA"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100065_bib411","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/mabi.201600137","article-title":"Reducible dimeric conjugates of small internally segment interfering RNA for efficient gene silencing","volume":"16","author":"Hong","year":"2016","journal-title":"Macromol Biosci"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib412","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1039\/C7SC03842A","article-title":"Caged circular siRNAs for photomodulation of gene expression in cells and mice","volume":"9","author":"Zhang","year":"2018","journal-title":"Chem Sci"},{"issue":"18","key":"10.1016\/j.pharmr.2025.100065_bib413","doi-asserted-by":"crossref","first-page":"10250","DOI":"10.1093\/nar\/gkab724","article-title":"Small circular interfering RNAs (sciRNAs) as a potent therapeutic platform for gene-silencing","volume":"49","author":"Jahns","year":"2021","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib414","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nbt1051","article-title":"Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy","volume":"23","author":"Kim","year":"2005","journal-title":"Nat Biotechnol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib415","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0092-8674(04)00258-2","article-title":"A Dicer-2-dependent 80s complex cleaves targeted mRNAs during RNAi in Drosophila","volume":"117","author":"Pham","year":"2004","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib416","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.cell.2005.10.022","article-title":"Human RISC couples microRNA biogenesis and posttranscriptional gene silencing","volume":"123","author":"Gregory","year":"2005","journal-title":"Cell"},{"issue":"24","key":"10.1016\/j.pharmr.2025.100065_bib417","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1101\/gad.1384005","article-title":"A human, ATP-independent, RISC assembly machine fueled by pre-miRNA","volume":"19","author":"Maniataki","year":"2005","journal-title":"Genes Dev"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100065_bib418","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1093\/nar\/gkp185","article-title":"Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells","volume":"37","author":"Zhou","year":"2009","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib419","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.phrs.2011.09.001","article-title":"Dicer-substrate siRNA inhibits tumor necrosis factor alpha secretion in Kupffer cells in vitro: In vivo targeting of Kupffer cells by siRNA-liposomes","volume":"65","author":"Pichu","year":"2012","journal-title":"Pharmacol Res"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100065_bib420","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/s41587-019-0205-0","article-title":"A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system","volume":"37","author":"Alterman","year":"2019","journal-title":"Nat Biotechnol"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib421","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1089\/nat.2013.0416","article-title":"Long double-stranded multiplex siRNAs for dual genes silencing","volume":"23","author":"Peng","year":"2013","journal-title":"Nucleic Acid Ther"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib422","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nbt1052","article-title":"Synthetic shRNAs as potent RNAi triggers","volume":"23","author":"Siolas","year":"2005","journal-title":"Nat Biotechnol"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100065_bib423","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2012.08.014","article-title":"Single-stranded siRNAs activate RNAi in animals","volume":"150","author":"Lima","year":"2012","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100065_bib424","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.cell.2012.08.002","article-title":"Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression","volume":"150","author":"Yu","year":"2012","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib425","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/0006-3002(58)90214-2","article-title":"5-Methyl cytosine in the RNA of Escherichia coli","volume":"29","author":"Amos","year":"1958","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100065_bib426","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/S0021-9258(18)69432-3","article-title":"Pseudouridine, a carbon-carbon linked ribonucleoside in ribonucleic acids: isolation, structure, and chemical characteristics","volume":"235","author":"Cohn","year":"1960","journal-title":"J Biol Chem"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100065_bib427","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.cell.2017.05.045","article-title":"Dynamic RNA modifications in gene expression regulation","volume":"169","author":"Roundtree","year":"2017","journal-title":"Cell"},{"issue":"D1","key":"10.1016\/j.pharmr.2025.100065_bib428","doi-asserted-by":"crossref","first-page":"D231","DOI":"10.1093\/nar\/gkab1083","article-title":"MODOMICS: a database of RNA modification pathways. 2021 update","volume":"50","author":"Boccaletto","year":"2022","journal-title":"Nucleic Acids Res"},{"issue":"21","key":"10.1016\/j.pharmr.2025.100065_bib429","doi-asserted-by":"crossref","first-page":"9645","DOI":"10.1021\/acs.jmedchem.6b00551","article-title":"The medicinal chemistry of therapeutic oligonucleotides","volume":"59","author":"Wan","year":"2016","journal-title":"J Med Chem"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100065_bib430","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Karik\u00f3","year":"2008","journal-title":"Mol Ther"},{"issue":"13","key":"10.1016\/j.pharmr.2025.100065_bib431","doi-asserted-by":"crossref","first-page":"7202","DOI":"10.1093\/nar\/gkab1241","article-title":"Membrane-dependent relief of translation elongation arrest on pseudouridine- and N1-methyl-pseudouridine-modified mRNAs","volume":"50","author":"Svitkin","year":"2022","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100065_bib432","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","article-title":"Drug delivery systems for RNA therapeutics","volume":"23","author":"Paunovska","year":"2022","journal-title":"Nat Rev Genet"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib433","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.pharmr.2025.100065_bib434","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1038\/1831815b0","article-title":"Induction of arginase in rabbit epithelium by the shope rabbit papilloma virus","volume":"183","author":"Rogers","year":"1959","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100065_bib435","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1084\/jem.134.6.1442","article-title":"Change in the structure of Shope papilloma virus-induced arginase associated with mutation of the virus","volume":"134","author":"Rogers","year":"1971","journal-title":"J Exp Med"},{"issue":"5067","key":"10.1016\/j.pharmr.2025.100065_bib436","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1038\/2121220a0","article-title":"Shope papilloma virus: a passenger in man and its significance to the potential control of the host genome","volume":"212","author":"Rogers","year":"1966","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib437","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1084\/jem.117.3.521","article-title":"Studies of the mechanism of action of the Shope rabbit papilloma virus. I. Concerning the nature of the induction of arginase in the infected cells","volume":"117","author":"Rogers","year":"1963","journal-title":"J Exp Med"},{"issue":"3833","key":"10.1016\/j.pharmr.2025.100065_bib438","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1126\/science.160.3833.1235","article-title":"Reaction of nitrosoguanidine (N-methyl-N\u2032-Nitro-N-nitrosoguanidine) with tobacco mosaic virus and its RNA","volume":"160","author":"Singer","year":"1968","journal-title":"Science"},{"issue":"5155","key":"10.1016\/j.pharmr.2025.100065_bib439","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/219749a0","article-title":"Use of viruses as carriers of added genetic information","volume":"219","author":"Rogers","year":"1968","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib440","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/BF00438893","article-title":"Hyperargininemia with arginase deficiency. A new familial metabolic disease. II. Biochemical studies","volume":"107","author":"Terheggen","year":"1970","journal-title":"Z Kinderheilkd"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib441","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/BF00438892","article-title":"Hyperargininemia wityh arginase deficiency. A new familial metabolic disease. I. Clinical studies","volume":"107","author":"Terheggen","year":"1970","journal-title":"Z Kinderheilkd"},{"key":"10.1016\/j.pharmr.2025.100065_bib442","article-title":"Virus is injected into 2 children in effort to alter chemical trait","volume":"28","author":"Schmeck","year":"1970","journal-title":"The New York Times"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib443","first-page":"1","article-title":"Unsuccessful trial of gene replacement in arginase deficiency","volume":"119","author":"Terheggen","year":"1975","journal-title":"Z Kinderheilkd"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib444","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0163-7258(85)90017-8","article-title":"Perspectives for gene therapy: inserting new genetic information into mammalian cells by physical techniques and viral vectors","volume":"29","author":"Cline","year":"1985","journal-title":"Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100065_bib445","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.4049\/jimmunol.142.11.3971","article-title":"Establishment and characterization of adenosine deaminase-deficient human T cell lines","volume":"142","author":"Kohn","year":"1989","journal-title":"J Immunol"},{"issue":"5058","key":"10.1016\/j.pharmr.2025.100065_bib446","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1126\/science.256.5058.808","article-title":"Hume gene therapy","volume":"256","author":"Anderson","year":"1992","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib447","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduc Target Ther"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib448","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.gene.2013.03.137","article-title":"History of gene therapy","volume":"525","author":"Wirth","year":"2013","journal-title":"Gene"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib449","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10258","article-title":"Viral vector-based gene therapies in the clinic","volume":"7","author":"Zhao","year":"2022","journal-title":"Bioeng Transl Med"},{"issue":"3685","key":"10.1016\/j.pharmr.2025.100065_bib450","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1126\/science.149.3685.754","article-title":"Adenovirus-associated defective virus particles","volume":"149","author":"Atchison","year":"1965","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib451","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1073\/pnas.56.1.86","article-title":"Nucleic acid from an adeno-associated virus: chemical and physical studies","volume":"56","author":"Rose","year":"1966","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib452","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1128\/JVI.73.2.939-947.1999","article-title":"Human adeno-associated virus type 5 is only distantly related to other known primate helper-dependent parvoviruses","volume":"73","author":"Bantel-Schaal","year":"1999","journal-title":"J Virol"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100065_bib453","doi-asserted-by":"crossref","first-page":"6823","DOI":"10.1128\/jvi.71.9.6823-6833.1997","article-title":"Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles","volume":"71","author":"Chiorini","year":"1997","journal-title":"J Virol"},{"issue":"18","key":"10.1016\/j.pharmr.2025.100065_bib454","doi-asserted-by":"crossref","first-page":"11854","DOI":"10.1073\/pnas.182412299","article-title":"Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy","volume":"99","author":"Gao","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib455","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.virol.2004.10.012","article-title":"Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein","volume":"330","author":"Mori","year":"2004","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib456","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1006\/viro.1996.0367","article-title":"Nucleotide sequencing and generation of an infectious clone of adeno-associated virus 3","volume":"221","author":"Muramatsu","year":"1996","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib457","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1128\/JVI.72.1.309-319.1998","article-title":"Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2","volume":"72","author":"Rutledge","year":"1998","journal-title":"J Virol"},{"issue":"17","key":"10.1016\/j.pharmr.2025.100065_bib458","doi-asserted-by":"crossref","first-page":"8911","DOI":"10.1128\/JVI.00672-08","article-title":"Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV (VR-942)","volume":"82","author":"Schmidt","year":"2008","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib459","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1128\/JVI.02012-07","article-title":"Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid-and heparan sulfate proteoglycan-independent transduction activity","volume":"82","author":"Schmidt","year":"2008","journal-title":"J Virol"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100065_bib460","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1128\/JVI.73.5.3994-4003.1999","article-title":"Gene therapy vectors based on adeno-associated virus type 1","volume":"73","author":"Xiao","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.pharmr.2025.100065_bib461","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.coviro.2016.08.003","article-title":"In vivo tissue-tropism of adeno-associated viral vectors","volume":"21","author":"Srivastava","year":"2016","journal-title":"Curr Opin Virol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib462","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1146\/annurev-virology-031413-085355","article-title":"AAV-mediated gene therapy for research and therapeutic purposes","volume":"1","author":"Samulski","year":"2014","journal-title":"Annu Rev Virol"},{"issue":"21","key":"10.1016\/j.pharmr.2025.100065_bib463","doi-asserted-by":"crossref","first-page":"10346","DOI":"10.1128\/JVI.00841-06","article-title":"Host cell DNA repair pathways in adeno-associated viral genome processing","volume":"80","author":"Choi","year":"2006","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib464","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","article-title":"Adeno-associated virus (AAV) as a vector for gene therapy","volume":"31","author":"Naso","year":"2017","journal-title":"BioDrugs"},{"key":"10.1016\/j.pharmr.2025.100065_bib465","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib466","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/mt.2009.258","article-title":"Characterization of genome integrity for oversized recombinant AAV vector","volume":"18","author":"Dong","year":"2010","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib467","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/mt.2009.255","article-title":"Effect of genome size on AAV vector packaging","volume":"18","author":"Wu","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.pharmr.2025.100065_bib468","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3389\/fimmu.2014.00350","article-title":"Cell-mediated immunity to AAV vectors, evolving concepts and potential solutions","volume":"5","author":"Basner-Tschakarjan","year":"2014","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib469","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1089\/hgtb.2012.243","article-title":"Pre-existing anti\u2013adeno-associated virus antibodies as a challenge in AAV gene therapy","volume":"24","author":"Louis Jeune","year":"2013","journal-title":"Hum Gene Ther Methods"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100065_bib470","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1038\/gt.2008.68","article-title":"Clinical gene therapy using recombinant adeno-associated virus vectors","volume":"15","author":"Mueller","year":"2008","journal-title":"Gene Ther"},{"issue":"24","key":"10.1016\/j.pharmr.2025.100065_bib471","doi-asserted-by":"crossref","first-page":"13150","DOI":"10.1128\/JVI.01415-13","article-title":"Comparative analysis of adeno-associated virus capsid stability and dynamics","volume":"87","author":"Rayaprolu","year":"2013","journal-title":"J Virol"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100065_bib472","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.coph.2010.06.007","article-title":"Viral vector-mediated RNA interference","volume":"10","author":"Couto","year":"2010","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.pharmr.2025.100065_bib473","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2024.148733","article-title":"Delivery of CRISPR\/Cas9 system by AAV as vectors for gene therapy","volume":"927","author":"Wang","year":"2024","journal-title":"Gene"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib474","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3181\/00379727-85-20825","article-title":"Recovery of new agent from patients with acute respiratory illness","volume":"85","author":"Hllleman","year":"1954","journal-title":"Proc Soc Exp Biol Med"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib475","doi-asserted-by":"crossref","DOI":"10.1099\/jgv.0.001721","article-title":"ICTV virus taxonomy profile: Adenoviridae 2022","volume":"103","author":"Benk\u0151","year":"2022","journal-title":"J Gen Virol"},{"key":"10.1016\/j.pharmr.2025.100065_bib476","series-title":"Manual of Clinical Microbiology. Carroll KC, ed.","author":"Heim","year":"2023"},{"key":"10.1016\/j.pharmr.2025.100065_bib477","series-title":"Adenoviridae. Fields Virology","author":"Berk","year":"2013"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib478","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/oxfordjournals.aje.a120913","volume":"89","author":"Fox","year":"1969","journal-title":"Am J Epidemiol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib479","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.bj.2021.08.009","article-title":"Human adenovirus infections in pediatric population-an update on clinico\u2013pathologic correlation","volume":"45","author":"Shieh","year":"2022","journal-title":"Biomed J"},{"issue":"5304","key":"10.1016\/j.pharmr.2025.100065_bib480","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1126\/science.275.5304.1320","article-title":"Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5","volume":"275","author":"Bergelson","year":"1997","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100065_bib481","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/nm952","article-title":"CD46 is a cellular receptor for group B adenoviruses","volume":"9","author":"Gaggar","year":"2003","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib482","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nm.2267","article-title":"The GD1a glycan is a cellular receptor for adenoviruses causing epidemic keratoconjunctivitis","volume":"17","author":"Nilsson","year":"2011","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100065_bib483","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1073\/pnas.94.7.3352","article-title":"HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses","volume":"94","author":"Tomko","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib484","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nm.2270","article-title":"Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14","volume":"17","author":"Wang","year":"2011","journal-title":"Nat Med"},{"issue":"13","key":"10.1016\/j.pharmr.2025.100065_bib485","doi-asserted-by":"crossref","first-page":"7227","DOI":"10.1128\/JVI.78.13.7227-7247.2004","article-title":"Gene transduction and cell entry pathway of fiber-modified adenovirus type 5 vectors carrying novel endocytic peptide ligands selected on human tracheal glandular cells","volume":"78","author":"Gaden","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.pharmr.2025.100065_bib486","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.virol.2015.03.006","article-title":"Adenovirus membrane penetration: tickling the tail of a sleeping dragon","volume":"479","author":"Wiethoff","year":"2015","journal-title":"Virology"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib487","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1128\/JVI.79.4.1992-2000.2005","article-title":"Adenovirus protein VI mediates membrane disruption following capsid disassembly","volume":"79","author":"Wiethoff","year":"2005","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib488","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/(SICI)1521-4141(199903)29:03<964::AID-IMMU964>3.0.CO;2-P","article-title":"Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells","volume":"29","author":"Zhong","year":"1999","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.pharmr.2025.100065_bib489","doi-asserted-by":"crossref","DOI":"10.1590\/1678-4685-gmb-2022-0079","article-title":"The use of adenoviral vectors in gene therapy and vaccine approaches","volume":"45","author":"Ara\u00fajo","year":"2022","journal-title":"Genet Mol Biol"},{"key":"10.1016\/j.pharmr.2025.100065_bib490","series-title":"Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases E-Book: 2-Volume Set","author":"Bennett","year":"2019"},{"key":"10.1016\/j.pharmr.2025.100065_bib491","series-title":"Wolters Kluwer Health Adis (ESP)","article-title":"Adenoviruses","author":"Wold","year":"2013"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100065_bib492","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1089\/hum.2004.15.1157","article-title":"The innate immune response to adenovirus vectors","volume":"15","author":"Muruve","year":"2004","journal-title":"Hum Gene Ther"},{"issue":"suppl 1","key":"10.1016\/j.pharmr.2025.100065_bib493","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1038\/sj.gt.3302612","article-title":"Gutless adenovirus: last-generation adenovirus for gene therapy","volume":"12","author":"Alba","year":"2005","journal-title":"Gene Ther"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100065_bib494","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1016\/j.ymthe.2023.09.018","article-title":"Intrathecal delivery of AAV-NDNF ameliorates disease progression of ALS mice","volume":"31","author":"Cheng","year":"2023","journal-title":"Mol Ther"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100065_bib495","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1016\/j.ymthe.2023.09.012","article-title":"Optimal delivery of RNA interference by viral vectors for cancer therapy","volume":"31","author":"Wong","year":"2023","journal-title":"Mol Ther"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100065_bib496","doi-asserted-by":"crossref","first-page":"4425","DOI":"10.1128\/jvi.71.6.4425-4435.1997","article-title":"In vitro assembly of virus-like particles with Rous sarcoma virus Gag deletion mutants: identification of the p10 domain as a morphological determinant in the formation of spherical particles","volume":"71","author":"Campbell","year":"1997","journal-title":"J Virol"},{"key":"10.1016\/j.pharmr.2025.100065_bib498","series-title":"The Retroviridae. Levy JA, ed","first-page":"19","author":"Coffin","year":"1992"},{"key":"10.1016\/j.pharmr.2025.100065_bib499","series-title":"Retroviruses","year":"1997"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib500","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1006\/mthe.2002.0549","article-title":"Comparison of various envelope proteins for their ability to pseudotype lentiviral vectors and transduce primitive hematopoietic cells from human blood","volume":"5","author":"Hanawa","year":"2002","journal-title":"Mol Ther"},{"issue":"14","key":"10.1016\/j.pharmr.2025.100065_bib501","doi-asserted-by":"crossref","first-page":"7791","DOI":"10.1073\/pnas.96.14.7791","article-title":"Recruitment of cyclin T1\/P-TEFb to an HIV type 1 long terminal repeat promoter proximal RNA target is both necessary and sufficient for full activation of transcription","volume":"96","author":"Bieniasz","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100065_bib502","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0960-9822(06)00335-6","article-title":"The importin-beta family member Crm1p bridges the interaction between Rev and the nuclear pore complex during nuclear export","volume":"7","author":"Neville","year":"1997","journal-title":"Curr Biol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib503","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/j.1460-2075.1988.tb02839.x","article-title":"Human immunodeficiency virus infection of CD4-bearing cells occurs by a pH-independent mechanism","volume":"7","author":"McClure","year":"1988","journal-title":"EMBO J"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib504","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/0014-5793(88)80551-9","article-title":"Quantitative measurement of fusion between human immunodeficiency virus and cultured cells using membrane fluorescence dequenching","volume":"239","author":"Sinangil","year":"1988","journal-title":"FEBS Lett"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100065_bib505","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/0092-8674(87)90542-3","article-title":"pH-independent HIV entry into CD4-positive T cells via virus envelope fusion to the plasma membrane","volume":"49","author":"Stein","year":"1987","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100065_bib506","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2174\/156652308786848021","article-title":"Mechanisms governing lentivirus integration site selection","volume":"8","author":"Ciuffi","year":"2008","journal-title":"Curr Gene Ther"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100065_bib507","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0001340","article-title":"Role of PSIP1\/LEDGF\/p75 in lentiviral infectivity and integration targeting","volume":"2","author":"Marshall","year":"2007","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmr.2025.100065_bib508","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.12659\/MSM.903094","article-title":"Prolonged integration site selection of a lentiviral vector in the genome of human keratinocytes","volume":"23","author":"Qian","year":"2017","journal-title":"Med Sci Monit"},{"issue":"5259","key":"10.1016\/j.pharmr.2025.100065_bib509","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1126\/science.272.5259.263","article-title":"In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector","volume":"272","author":"Naldini","year":"1996","journal-title":"Science"},{"issue":"5030","key":"10.1016\/j.pharmr.2025.100065_bib510","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1126\/science.1925601","article-title":"Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection","volume":"254","author":"Bukrinsky","year":"1991","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100065_bib511","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1089\/10430340252837242","article-title":"Role of hepatocyte direct hyperplasia in lentivirus-mediated liver transduction in vivo","volume":"13","author":"Ohashi","year":"2002","journal-title":"Hum Gene Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib512","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/71673","article-title":"Efficient lentiviral transduction of liver requires cell cycling in vivo","volume":"24","author":"Park","year":"2000","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib513","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/s12967-016-1047-x","article-title":"Retroviral vectors and transposons for stable gene therapy: advances, current challenges and perspectives","volume":"14","author":"Vargas","year":"2016","journal-title":"J Transl Med"},{"key":"10.1016\/j.pharmr.2025.100065_bib514","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2016.17","article-title":"Production of lentiviral vectors","volume":"3","author":"Merten","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100065_bib515","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2174\/156652309790031120","article-title":"State-of-the-art lentiviral vectors for research use: risk assessment and biosafety recommendations","volume":"9","author":"Pauwels","year":"2009","journal-title":"Curr Gene Ther"},{"key":"10.1016\/j.pharmr.2025.100065_bib516","series-title":"Gene Therapy - Tools and Potential Applications. Mart\u00edn-Molina F, ed.","author":"Tom\u00e1s","year":"2013"},{"issue":"16","key":"10.1016\/j.pharmr.2025.100065_bib517","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100065_bib519","volume":"2","author":"Lesmana","year":"2024","journal-title":"Genet Med Open"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100065_bib520","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100065_bib521","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2471\/BLT.19.237149","article-title":"Herpes simplex virus: global infection prevalence and incidence estimates, 2016","volume":"98","author":"James","year":"2020","journal-title":"Bull World Health Organ"},{"issue":"9267","key":"10.1016\/j.pharmr.2025.100065_bib522","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(00)04638-9","article-title":"Herpes simplex virus infections","volume":"357","author":"Whitley","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100065_bib523","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2020.617578","article-title":"Herpes simplex virus cell entry mechanisms: an update","volume":"10","author":"Madavaraju","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100065_bib524","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.3390\/v13091849","article-title":"Two sides to every story: herpes simplex type-1 viral glycoproteins gB, gD, gH\/gL, gK, and cellular receptors function as key players in membrane fusion","volume":"13","author":"Jambunathan","year":"2021","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib525","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1006\/viro.2001.1041","article-title":"Transcription from the gene encoding the herpesvirus entry receptor nectin-1 (HveC) in nervous tissue of adult mouse","volume":"287","author":"Haarr","year":"2001","journal-title":"Virology"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100065_bib526","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006741","article-title":"The pUL37 tegument protein guides alpha-herpesvirus retrograde axonal transport to promote neuroinvasion","volume":"13","author":"Richards","year":"2017","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.pharmr.2025.100065_bib527","doi-asserted-by":"crossref","first-page":"171","DOI":"10.21775\/cimb.041.171","article-title":"Navigating the cytoplasm: delivery of the alphaherpesvirus genome to the nucleus","volume":"41","author":"Smith","year":"2021","journal-title":"Curr Issues Mol Biol"},{"key":"10.1016\/j.pharmr.2025.100065_bib528","series-title":"Fields Virology","first-page":"235","author":"Knipe","year":"2021"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib529","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3109\/13550289509111007","article-title":"Herpes simplex virus latent infection in the nervous system","volume":"1","author":"Steiner","year":"1995","journal-title":"J Neurovirol"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib530","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1128\/JVI.06010-11","article-title":"Role of specific innate immune responses in herpes simplex virus infection of the central nervous system","volume":"86","author":"Wang","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.pharmr.2025.100065_bib531","first-page":"123","article-title":"HSV recombinant vectors for gene therapy","volume":"4","author":"Manservigi","year":"2010","journal-title":"Open Virol J"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100065_bib532","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/sj.gt.3300766","article-title":"Deletion of multiple immediate\u2013early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons","volume":"5","author":"Krisky","year":"1998","journal-title":"Gene Ther"},{"issue":"13","key":"10.1016\/j.pharmr.2025.100065_bib533","doi-asserted-by":"crossref","first-page":"E1632","DOI":"10.1073\/pnas.1423556112","article-title":"Herpes simplex viral-vector design for efficient transduction of nonneuronal cells without cytotoxicity","volume":"112","author":"Miyagawa","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib534","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1128\/JVI.72.4.3307-3320.1998","article-title":"Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins","volume":"72","author":"Samaniego","year":"1998","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib535","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/s41598-017-01635-1","article-title":"Engineered HSV vector achieves safe long-term transgene expression in the central nervous system","volume":"7","author":"Verlengia","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.pharmr.2025.100065_bib536","article-title":"Non-replicative herpes simplex virus genomic and amplicon vectors for gene therapy\u2014an update","author":"Le Hars","year":"2024","journal-title":"Gene Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib537","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0092-8674(82)90035-6","article-title":"The herpes simplex virus amplicon: a new eucaryotic defective-virus cloning-amplifying vector","volume":"30","author":"Spaete","year":"1982","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100065_bib538","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1128\/jvi.66.5.2952-2965.1992","article-title":"Cytotoxicity of a replication-defective mutant of herpes simplex virus type 1","volume":"66","author":"Johnson","year":"1992","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib539","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1006\/mthe.2001.0294","article-title":"Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome","volume":"3","author":"Saeki","year":"2001","journal-title":"Mol Ther"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100065_bib540","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1089\/104303403322124774","article-title":"Improved packaging system for generation of high-level noncytotoxic HSV-1 amplicon vectors using Cre-loxP site-specific recombination to delete the packaging signals of defective helper genomes","volume":"14","author":"Zaupa","year":"2003","journal-title":"Hum Gene Ther"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100065_bib541","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1128\/JVI.77.6.3768-3776.2003","article-title":"Deletion of the virion host shutoff protein (vhs) from herpes simplex virus (HSV) relieves the viral block to dendritic cell activation: potential of vhs- HSV vectors for dendritic cell-mediated immunotherapy","volume":"77","author":"Samady","year":"2003","journal-title":"J Virol"},{"issue":"Suppl 1","key":"10.1016\/j.pharmr.2025.100065_bib542","first-page":"S1","article-title":"Herpes simplex virus virulence: the functions of the gamma (1)34.5 gene","volume":"3","author":"Roizman","year":"1997","journal-title":"J Neurovirol"},{"key":"10.1016\/j.pharmr.2025.100065_bib543","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0074-7742(03)01007-9","article-title":"Oncolytic herpes simplex virus for tumor therapy","volume":"55","author":"Hu","year":"2003","journal-title":"Int Rev Neurobiol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib544","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.pharmr.2025.100065_bib545","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202002022","article-title":"Therapeutic RNA delivery for COVID and other diseases","volume":"10","author":"Dobrowolski","year":"2021","journal-title":"Adv Healthc Mater"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100065_bib546","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1021\/acsmaterialsau.3c00032","article-title":"Lipid-based nanoparticles for drug\/gene delivery: an overview of the production techniques and difficulties encountered in their industrial development","volume":"3","author":"Mehta","year":"2023","journal-title":"ACS Mater Au"},{"key":"10.1016\/j.pharmr.2025.100065_bib547","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.addr.2020.12.014","article-title":"Self-assembled mRNA vaccines","volume":"170","author":"Kim","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.pharmr.2025.100065_bib548","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jconrel.2021.03.043","article-title":"The dawn of mRNA vaccines: the COVID-19 case","volume":"333","author":"Verbeke","year":"2021","journal-title":"J Control Release"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib549","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1567-5394(02)00132-9","article-title":"Cationic lipid\u2013DNA complexes\u2014lipoplexes\u2014for gene transfer and therapy","volume":"58","author":"Zhdanov","year":"2002","journal-title":"Bioelectrochemistry"},{"key":"10.1016\/j.pharmr.2025.100065_bib550","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat Rev Mater"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib551","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3390\/pharmaceutics14040821","article-title":"Targeted liposomes: a nonviral gene delivery system for cancer therapy","volume":"14","author":"Luiz","year":"2022","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100065_bib552","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.109804","article-title":"Optimized lipid nanoparticles (LNPs) for organ-selective nucleic acids delivery in vivo","volume":"27","author":"Zhang","year":"2024","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib553","doi-asserted-by":"crossref","first-page":"7233","DOI":"10.1038\/s41467-021-27493-0","article-title":"An ionizable lipid toolbox for RNA delivery","volume":"12","author":"Han","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.pharmr.2025.100065_bib554","doi-asserted-by":"crossref","unstructured":"Steffes V, MacDonald S, Crowe J, et al. Lipids with negative spontaneous curvature decrease the solubility of the cancer drug paclitaxel in liposomes. Preprint. Posted online Ocober 21, 2023. bioRxiv, 2023.2010.2018.563006. https:\/\/doi.org\/10.1101\/2023.10.18.563006.","DOI":"10.1101\/2023.10.18.563006"},{"issue":"14","key":"10.1016\/j.pharmr.2025.100065_bib555","article-title":"Nanoparticles containing oxidized cholesterol deliver mRNA to the liver microenvironment at clinically relevant doses","volume":"31","author":"Paunovska","year":"2019","journal-title":"Adv Mater"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100065_bib556","doi-asserted-by":"crossref","first-page":"8341","DOI":"10.1021\/acsnano.8b03640","article-title":"Analyzing 2000 in vivo drug delivery data points reveals cholesterol structure impacts nanoparticle delivery","volume":"12","author":"Paunovska","year":"2018","journal-title":"ACS Nano"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib557","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrm2336","article-title":"Cellular cholesterol trafficking and compartmentalization","volume":"9","author":"Ikonen","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"23-24","key":"10.1016\/j.pharmr.2025.100065_bib558","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.cca.2010.08.038","article-title":"Mechanisms of LDL oxidation","volume":"411","author":"Yoshida","year":"2010","journal-title":"Clin Chim Acta"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100065_bib559","doi-asserted-by":"crossref","first-page":"4289","DOI":"10.1039\/D0BM01947J","article-title":"Illuminating endosomal escape of polymorphic lipid nanoparticles that boost mRNA delivery","volume":"9","author":"Herrera","year":"2021","journal-title":"Biomater Sci"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100065_bib560","article-title":"Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles","volume":"2","author":"Mui","year":"2013","journal-title":"Mol Ther Nucleic Acids"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100065_bib561","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1021\/acs.bioconjchem.3c00174","article-title":"PEGylated lipid nanoparticle formulations: immunological safety and efficiency perspective","volume":"34","author":"Tenchov","year":"2023","journal-title":"Bioconjug Chem"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100065_bib562","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0169-409X(02)00046-7","article-title":"Prospects for cationic polymers in gene and oligonucleotide therapy against cancer","volume":"54","author":"Merdan","year":"2002","journal-title":"Adv Drug Deliv Rev"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100065_bib563","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.7150\/thno.15710","article-title":"Combination therapy for ulcerative colitis: orally targeted nanoparticles prevent mucosal damage and relieve inflammation","volume":"6","author":"Xiao","year":"2016","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib564","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0005-2787(74)90277-9","article-title":"Uptake of polynucleotides by mammalian cells: XIV. Stimulation of the uptake of polynucleotides by poly(l-lysine)","volume":"340","author":"Schell","year":"1974","journal-title":"Biochim Biophys Acta"},{"issue":"33","key":"10.1016\/j.pharmr.2025.100065_bib565","doi-asserted-by":"crossref","first-page":"8613","DOI":"10.1016\/j.biomaterials.2011.07.047","article-title":"The association of autophagy with polyethylenimine-induced cytotoxity in nephritic and hepatic cell lines","volume":"32","author":"Gao","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.pharmr.2025.100065_bib566","doi-asserted-by":"crossref","first-page":"14454","DOI":"10.1073\/pnas.0703882104","article-title":"Breaking up the correlation between efficacy and toxicity for nonviral gene delivery","volume":"104","author":"Breunig","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib567","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0167-4781(00)00220-7","article-title":"Polymer chemical structure is a key determinant of physicochemical and colloidal properties of polymer\u2013DNA complexes for gene delivery","volume":"1517","author":"Jones","year":"2000","journal-title":"Biochim Biophys Acta"},{"issue":"1-2","key":"10.1016\/j.pharmr.2025.100065_bib568","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ijpharm.2008.09.039","article-title":"Polymeric nanoparticles for siRNA delivery and gene silencing","volume":"367","author":"Patil","year":"2009","journal-title":"Int J Pharm"},{"issue":"32","key":"10.1016\/j.pharmr.2025.100065_bib569","doi-asserted-by":"crossref","first-page":"35835","DOI":"10.1021\/acsami.0c08268","article-title":"Surface-functionalized PEGylated nanoparticles deliver messenger RNA to pulmonary immune cells","volume":"12","author":"Ke","year":"2020","journal-title":"ACS Appl Mater Interfaces"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib570","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s13346-020-00725-4","article-title":"Optimization of an mRNA vaccine assisted with cyclodextrin-polyethyleneimine conjugates","volume":"10","author":"Tan","year":"2020","journal-title":"Drug Deliv Transl Res"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib571","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s41061-017-0114-y","article-title":"Polysaccharide-based nanoparticles for gene delivery","volume":"375","author":"Huh","year":"2017","journal-title":"Top Curr Chem (Cham)"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100065_bib572","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.1016\/j.actbio.2012.09.022","article-title":"Polysaccharide gene transfection agents","volume":"8","author":"Khan","year":"2012","journal-title":"Acta Biomater"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib573","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejpb.2010.09.014","article-title":"Chitosan-graft-spermine as a gene carrier in vitro and in vivo","volume":"77","author":"Jiang","year":"2011","journal-title":"Eur J Pharm Biopharm"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100065_bib574","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.biomaterials.2008.12.005","article-title":"Akt1 silencing efficiencies in lung cancer cells by sh\/si\/ssiRNA transfection using a reductable polyspermine carrier","volume":"30","author":"Jere","year":"2009","journal-title":"Biomaterials"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib575","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/cbf.290010302","article-title":"Biochemistry of the polyamines","volume":"1","author":"Allen","year":"1983","journal-title":"Cell Biochem Funct"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100065_bib576","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1023\/B:PHAM.0000026437.32238.6f","article-title":"A method for oral DNA delivery with N-acetylated chitosan","volume":"21","author":"Kai","year":"2004","journal-title":"Pharm Res"},{"key":"10.1016\/j.pharmr.2025.100065_bib577","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.ijbiomac.2019.07.049","article-title":"Safe and efficient gene delivery based on rice bran polysaccharide","volume":"137","author":"Wu","year":"2019","journal-title":"Int J Biol Macromol"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100065_bib578","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1016\/j.bmc.2010.04.031","article-title":"Liver-targeted siRNA delivery by polyethylenimine (PEI)-pullulan carrier","volume":"18","author":"Kang","year":"2010","journal-title":"Bioorg Med Chem"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib579","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3390\/biomedicines6020051","article-title":"Cell-penetrating peptides to enhance delivery of oligonucleotide-based therapeutics","volume":"6","author":"McClorey","year":"2018","journal-title":"Biomedicines"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100065_bib580","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1038\/nbt759","article-title":"Systemically delivered antisense oligomers upregulate gene expression in mouse tissues","volume":"20","author":"Sazani","year":"2002","journal-title":"Nat Biotechnol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib581","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1021\/bc050283q","article-title":"Evaluation of cell-penetrating peptides (CPPs) as vehicles for intracellular delivery of antisense peptide nucleic acid (PNA)","volume":"17","author":"Bendifallah","year":"2006","journal-title":"Bioconjug Chem"},{"issue":"24","key":"10.1016\/j.pharmr.2025.100065_bib582","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1093\/hmg\/ddn293","article-title":"Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function","volume":"17","author":"Yin","year":"2008","journal-title":"Hum Mol Genet"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib583","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/nm.3765","article-title":"Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers","volume":"21","author":"Goyenvalle","year":"2015","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100065_bib584","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1039\/C8TB03124J","article-title":"Peptide-based gene delivery vectors","volume":"7","author":"Kang","year":"2019","journal-title":"J Mater Chem B"},{"key":"10.1016\/j.pharmr.2025.100065_bib585","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.actbio.2020.09.027","article-title":"Peptides as a material platform for gene delivery: Emerging concepts and converging technologies","volume":"117","author":"Urello","year":"2020","journal-title":"Acta Biomater"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib586","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1039\/C6TB02862D","article-title":"Histidine-enriched multifunctional peptide vectors with enhanced cellular uptake and endosomal escape for gene delivery","volume":"5","author":"Meng","year":"2017","journal-title":"J Mater Chem B"},{"issue":"46","key":"10.1016\/j.pharmr.2025.100065_bib587","doi-asserted-by":"crossref","first-page":"16126","DOI":"10.1021\/la303299s","article-title":"Selective gene delivery to cancer cells using an integrated cationic amphiphilic peptide","volume":"28","author":"Tang","year":"2012","journal-title":"Langmuir"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib588","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.cocis.2007.05.004","article-title":"Biomimetic amphiphiles: biosurfactants","volume":"12","author":"Lu","year":"2007","journal-title":"Curr Opin Colloid Interface Sci"},{"key":"10.1016\/j.pharmr.2025.100065_bib589","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/469261","article-title":"Molecular design and applications of self-assembling surfactant-like peptides","volume":"2013","author":"Tang","year":"2013","journal-title":"J Nanomater"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib590","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.nantod.2009.02.009","article-title":"Designer self-assembling peptide nanomaterials","volume":"4","author":"Yanlian","year":"2009","journal-title":"Nano Today"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100065_bib591","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1021\/ar300034v","article-title":"Lipid-like self-assembling peptides","volume":"45","author":"Zhang","year":"2012","journal-title":"Acc Chem Res"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib592","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1021\/nn5044838","article-title":"Peptide nanofiber complexes with siRNA for deep brain gene silencing by stereotactic neurosurgery","volume":"9","author":"Mazza","year":"2015","journal-title":"ACS Nano"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100065_bib593","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/biosci\/biv084","article-title":"Extracellular vesicles: composition, biological relevance, and methods of study","volume":"65","author":"Zaborowski","year":"2015","journal-title":"Bioscience"},{"key":"10.1016\/j.pharmr.2025.100065_bib594","doi-asserted-by":"crossref","DOI":"10.3402\/jev.v4.27066","article-title":"Biological properties of extracellular vesicles and their physiological functions","volume":"4","author":"Y\u00e1\u00f1ez-M\u00f3","year":"2015","journal-title":"J Extracell Vesicles"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100065_bib595","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1590\/1414-431X20132964","article-title":"Extracellular vesicles: structure, function, and potential clinical uses in renal diseases","volume":"46","author":"Borges","year":"2013","journal-title":"Braz J Med Biol Res"},{"issue":"13","key":"10.1016\/j.pharmr.2025.100065_bib596","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.3390\/ijms25137333","article-title":"Viral and non-viral systems to deliver gene therapeutics to clinical targets","volume":"25","author":"Taghdiri","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pharmr.2025.100065_bib597","doi-asserted-by":"crossref","DOI":"10.1038\/srep11295","article-title":"Serum exosome microRNA as a minimally-invasive early biomarker of AML","volume":"5","author":"Hornick","year":"2015","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100065_bib598","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0078115","article-title":"MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid (CSF): a platform for glioblastoma biomarker development","volume":"8","author":"Akers","year":"2013","journal-title":"PLoS One"},{"issue":"29","key":"10.1016\/j.pharmr.2025.100065_bib599","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.4699","article-title":"Exosomal levels of miRNA-21 from cerebrospinal fluids associated with poor prognosis and tumor recurrence of glioma patients","volume":"6","author":"Shi","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib600","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12885-018-4006-5","article-title":"An elevated expression of serum exosomal microRNA-191,\u2212 21,\u2212 451a of pancreatic neoplasm is considered to be efficient diagnostic marker","volume":"18","author":"Goto","year":"2018","journal-title":"BMC Cancer"},{"issue":"36","key":"10.1016\/j.pharmr.2025.100065_bib601","doi-asserted-by":"crossref","first-page":"13368","DOI":"10.1073\/pnas.0403453101","article-title":"Identification and proteomic profiling of exosomes in human urine","volume":"101","author":"Pisitkun","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100065_bib602","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.devcel.2007.04.005","article-title":"Coats, tethers, Rabs, and SNAREs work together to mediate the intracellular destination of a transport vesicle","volume":"12","author":"Cai","year":"2007","journal-title":"Dev Cell"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100065_bib603","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/cdd.2012.25","article-title":"How apoptotic cells aid in the removal of their own cold dead bodies","volume":"19","author":"Wickman","year":"2012","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.pharmr.2025.100065_bib604","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/1471-2407-11-108","article-title":"Interaction and uptake of exosomes by ovarian cancer cells","volume":"11","author":"Escrevente","year":"2011","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib605","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/bjc.1972.33","article-title":"Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics","volume":"26","author":"Kerr","year":"1972","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100065_bib606","doi-asserted-by":"crossref","first-page":"7309","DOI":"10.4049\/jimmunol.166.12.7309","article-title":"Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles","volume":"166","author":"Th\u00e9ry","year":"2001","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100065_bib607","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.biotechadv.2012.08.008","article-title":"Exosomes for drug delivery\u2014a novel application for the mesenchymal stem cell","volume":"31","author":"Lai","year":"2013","journal-title":"Biotechnol Adv"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100065_bib608","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.14336\/AD.2021.0708","article-title":"Therapeutic potential of nucleic acids when combined with extracellular vesicles","volume":"12","author":"Jurgielewicz","year":"2021","journal-title":"Aging Dis"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib609","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1208\/s12248-018-0211-z","article-title":"Therapeutic potential of engineered extracellular vesicles","volume":"20","author":"Mentkowski","year":"2018","journal-title":"AAPS J"},{"key":"10.1016\/j.pharmr.2025.100065_bib610","doi-asserted-by":"crossref","DOI":"10.3402\/jev.v4.26316","article-title":"Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting","volume":"4","author":"Wiklander","year":"2015","journal-title":"J Extracell Vesicles"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib611","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s11671-020-03399-6","article-title":"Kinetics and specificity of HEK293T extracellular vesicle uptake using imaging flow cytometry","volume":"15","author":"Jurgielewicz","year":"2002","journal-title":"Nanoscale Res Lett"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib612","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1021\/acs.bioconjchem.9b00085","article-title":"Harnessing exosomes for the development of brain drug delivery systems","volume":"30","author":"Zheng","year":"2019","journal-title":"Bioconjug Chem"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib613","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nbt.1807","article-title":"Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes","volume":"29","author":"Alvarez-Erviti","year":"2011","journal-title":"Nat Biotechnol"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100065_bib614","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","article-title":"Drug transport across the blood-brain barrier","volume":"32","author":"Pardridge","year":"2012","journal-title":"J Cereb Blood Flow Metab"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib615","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s12195-016-0458-3","article-title":"Elucidation of exosome migration across the blood-brain barrier model in vitro","volume":"9","author":"Chen","year":"2016","journal-title":"Cell Mol Bioeng"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib616","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3390\/cells9040851","article-title":"Targeting and crossing the blood-brain barrier with extracellular vesicles","volume":"9","author":"Saint-Pol","year":"2020","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100065_bib617","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1007\/s12975-017-0599-2","article-title":"Human neural stem cell extracellular vesicles improve tissue and functional recovery in the murine thromboembolic stroke model","volume":"9","author":"Webb","year":"2018","journal-title":"Transl Stroke Res"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100065_bib618","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1161\/STROKEAHA.117.020353","article-title":"Human neural stem cell extracellular vesicles improve recovery in a porcine model of ischemic stroke","volume":"49","author":"Webb","year":"2018","journal-title":"Stroke"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib619","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12951-024-02298-7","article-title":"Exosome-based delivery strategies for tumor therapy: an update on modification, loading, and clinical application","volume":"22","author":"Yang","year":"2024","journal-title":"J Nanobiotechnol"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib620","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/mt.2008.1","article-title":"Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer","volume":"16","author":"Dai","year":"2008","journal-title":"Mol Ther"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100065_bib621","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1089\/scd.2020.0080","article-title":"Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19","volume":"29","author":"Sengupta","year":"2020","journal-title":"Stem Cells Dev"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib622","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab588","article-title":"Real-life effectiveness and safety of baricitinib as adjunctive to standard-of-care treatment in hospitalized patients with severe coronavirus disease 2019","volume":"9","author":"Tziolos","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib623","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12964-022-00959-4","article-title":"A review on exosomes application in clinical trials: perspective, questions, and challenges","volume":"20","author":"RezaieJ","year":"2022","journal-title":"Cell Commun Signal"},{"issue":"1-2","key":"10.1016\/j.pharmr.2025.100065_bib624","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ijpharm.2017.02.038","article-title":"Exosomes as novel bio-carriers for gene and drug delivery","volume":"521","author":"Jiang","year":"2017","journal-title":"Int J Pharm"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100065_bib625","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41565-021-00931-2","article-title":"Extracellular vesicles as a next-generation drug delivery platform","volume":"16","author":"Herrmann","year":"2021","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.pharmr.2025.100065_bib626","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ymeth.2019.11.007","article-title":"Extracellular blebs: artificially-induced extracellular vesicles for facile production and clinical translation","volume":"177","author":"Thone","year":"2020","journal-title":"Methods"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100065_bib627","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1021\/acs.molpharmaceut.5b00364","article-title":"Exogenous DNA loading into extracellular vesicles via electroporation is size-dependent and enables limited gene delivery","volume":"12","author":"Lamichhane","year":"2015","journal-title":"Mol Pharm"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100065_bib628","doi-asserted-by":"crossref","first-page":"E1433","DOI":"10.1073\/pnas.1418401112","article-title":"Differential fates of biomolecules delivered to target cells via extracellular vesicles","volume":"112","author":"Kanada","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"10.1016\/j.pharmr.2025.100065_bib629","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.3390\/ijms20194684","article-title":"Challenges in exosome isolation and analysis in health and disease","volume":"20","author":"Ludwig","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib630","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/mt.2012.180","article-title":"Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells","volume":"21","author":"Ohno","year":"2013","journal-title":"Mol Ther"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib631","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0223-5","article-title":"Extracellular vesicle-based therapeutics: natural versus engineered targeting and trafficking","volume":"51","author":"Murphy","year":"2019","journal-title":"Exp Mol Med"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib632","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3390\/pharmaceutics13030396","article-title":"The ins and outs of messenger RNA electroporation for physical gene delivery in immune cell-based therapy","volume":"13","author":"Campillo-Davo","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.pharmr.2025.100065_bib633","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1146\/annurev-bioeng-110220-023800","article-title":"Recent advancements in electroporation technologies: from bench to clinic","volume":"25","author":"Campelo","year":"2023","journal-title":"Annu Rev Biomed Eng"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100065_bib634","article-title":"In vivo editing of the human mutant rhodopsin gene by electroporation of plasmid-based CRISPR\/Cas9 in the mouse retina","volume":"5","author":"Latella","year":"2016","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.pharmr.2025.100065_bib635","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jconrel.2016.05.052","article-title":"Non-invasive, neuron-specific gene therapy by focused ultrasound-induced blood-brain barrier opening in Parkinson's disease mouse model","volume":"235","author":"Lin","year":"2016","journal-title":"J Control Release"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib636","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/cvr\/cvaa077","article-title":"Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin\/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1","volume":"117","author":"Landmesser","year":"2021","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharmr.2025.100065_bib637","year":"2024","journal-title":"Business Research Insights"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100065_bib639","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/d41573-020-00078-0","article-title":"RNA therapeutics on the rise","volume":"19","author":"Wang","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100065_bib640","first-page":"347","article-title":"Antisense oligonucleotides: basic concepts and mechanisms","volume":"1","author":"Dias","year":"2002","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib641","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1021\/acs.chemrev.3c00611","article-title":"Chemically modified platforms for better RNA therapeutics","volume":"124","author":"Shi","year":"2024","journal-title":"Chem Rev"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib642","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s43856-023-00419-1","article-title":"Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders","volume":"4","author":"Lauffer","year":"2024","journal-title":"Commun Med (Lond)"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100065_bib643","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.3390\/jcm9062004","article-title":"Antisense oligonucleotides: an emerging area in drug discovery and development","volume":"9","author":"Dhuri","year":"2020","journal-title":"J Clin Med"},{"issue":"24","key":"10.1016\/j.pharmr.2025.100065_bib644","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","article-title":"Targeting Huntingtin expression in patients with Huntington's disease","volume":"380","author":"Tabrizi","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib645","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0002-9394(02)01327-2","article-title":"A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS","volume":"133","year":"2002","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib646","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2165\/00003088-200241040-00002","article-title":"Fomivirsen: clinical pharmacology and potential drug interactions","volume":"41","author":"Geary","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.pharmr.2025.100065_bib647","doi-asserted-by":"crossref","first-page":"5","DOI":"10.21037\/aes-21-18","article-title":"Cytomegalovirus retinitis in the highly active anti-retroviral therapy era","volume":"7","author":"Ude","year":"2022","journal-title":"Ann Eye Sci"},{"key":"10.1016\/j.pharmr.2025.100065_bib648","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107967","article-title":"Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination","volume":"230","author":"Yu","year":"2022","journal-title":"Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100065_bib649","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.2165\/00003495-200868080-00002","article-title":"Neovascular age-related macular degeneration: potential therapies","volume":"68","author":"Chappelow","year":"2008","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100065_bib650","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1016\/j.ophtha.2007.02.021","article-title":"Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration","volume":"114","author":"Macugen AMD Study Group","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.pharmr.2025.100065_bib651","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/ncpcardio0836","article-title":"Mechanisms of Disease: genetic causes of familial hypercholesterolemia","volume":"4","author":"Soutar","year":"2007","journal-title":"Nat Clin Pract Cardiovasc Med"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib652","first-page":"119","article-title":"Mipomersen (kynamro): a novel antisense oligonucleotide inhibitor for the management of homozygous familial hypercholesterolemia","volume":"39","author":"Wong","year":"2014","journal-title":"P T"},{"key":"10.1016\/j.pharmr.2025.100065_bib653","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2147\/VHRM.S191965","article-title":"Mipomersen in familial hypercholesterolemia: an update on health-related quality of life and patient-reported outcomes","volume":"18","author":"Chambergo-Michilot","year":"2022","journal-title":"Vasc Health Risk Manag"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100065_bib654","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/humu.22390","article-title":"The TREAT-NMD Duchenne muscular dystrophy registries: conception, design, and utilization by industry and academia","volume":"34","author":"Bladen","year":"2013","journal-title":"Hum Mutat"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100065_bib655","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.nmd.2014.03.008","article-title":"A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy","volume":"24","author":"Mah","year":"2014","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib656","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13023-017-0631-3","article-title":"The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review","volume":"12","author":"Ryder","year":"2017","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib657","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/mus.20586","article-title":"Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule","volume":"34","author":"Aartsma-Rus","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.pharmr.2025.100065_bib658","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0074-7696(07)65005-0","article-title":"Biology of the striated muscle dystrophin-glycoprotein complex","volume":"265","author":"Ervasti","year":"2008","journal-title":"Int Rev Cytol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib659","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/BF00858725","article-title":"The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. I. Natural history","volume":"240","author":"Bushby","year":"1993","journal-title":"J Neurol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib660","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40265-020-01267-2","article-title":"Golodirsen: first approval","volume":"80","author":"Heo","year":"2020","journal-title":"Drugs"},{"issue":"17","key":"10.1016\/j.pharmr.2025.100065_bib661","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s40265-016-0657-1","article-title":"Eteplirsen: first global approval","volume":"76","author":"Syed","year":"2016","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib662","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1007\/s12325-024-02801-4","article-title":"Evolving role of viltolarsen for treatment of duchenne muscular dystrophy","volume":"41","author":"Vincik","year":"2024","journal-title":"Adv Ther"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib663","doi-asserted-by":"crossref","first-page":"778","DOI":"10.3390\/pharmaceutics15030778","article-title":"Recent trends in antisense therapies for duchenne muscular dystrophy","volume":"15","author":"Wilton-Clark","year":"2023","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib664","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.ajhg.2008.01.014","article-title":"Antisense masking of an hnRNP A1\/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice","volume":"82","author":"Hua","year":"2008","journal-title":"Am J Hum Genet"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib665","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40265-017-0711-7","article-title":"Nusinersen: first global approval","volume":"77","author":"Hoy","year":"2017","journal-title":"Drugs"},{"issue":"15","key":"10.1016\/j.pharmr.2025.100065_bib666","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1101\/gad.1941310","article-title":"Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model","volume":"24","author":"Hua","year":"2010","journal-title":"Genes Dev"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100065_bib667","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11883-020-00836-w","article-title":"Efficacy and safety of volanesorsen (ISIS 304801): the evidence from phase 2 and 3 clinical trials","volume":"22","author":"Fogacci","year":"2020","journal-title":"Curr Atheroscler Rep"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib668","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1089\/nat.2023.0027","article-title":"From failure to meet the clinical endpoint to U.S. Food and Drug Administration approval: 15th antisense oligonucleotide therapy approved qalsody (tofersen) for treatment of SOD1 mutated amyotrophic lateral sclerosis","volume":"33","author":"van Roon-Mom","year":"2023","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.pharmr.2025.100065_bib669","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.2147\/DDDT.S162913","article-title":"Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis","volume":"13","author":"Mathew","year":"2019","journal-title":"Drug Des Devel Ther"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib670","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40120-020-00208-1","article-title":"A review of patisiran (ONPATTRO\u00ae) for the treatment of polyneuropathy in people with hereditary transthyretin amyloidosis","volume":"9","author":"Urits","year":"2020","journal-title":"Neurol Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib671","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2217\/nmt-2018-0033","article-title":"Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis","volume":"9","author":"Kristen","year":"2019","journal-title":"Neurodegener Dis Manag"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100065_bib672","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1358\/dot.2019.55.5.2958475","article-title":"Patisiran for the treatment of patients with familial amyloid polyneuropathy","volume":"55","author":"Rizk","year":"2019","journal-title":"Drugs Today (Barc)"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib673","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/jcph.1480","article-title":"Patisiran pharmacokinetics, pharmacodynamics, and exposure-response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin-mediated (hATTR) amyloidosis","volume":"60","author":"Zhang","year":"2020","journal-title":"J Clin Pharmacol"},{"issue":"13","key":"10.1016\/j.pharmr.2025.100065_bib674","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s40265-018-0968-5","article-title":"Inotersen: first global approval","volume":"78","author":"Keam","year":"2018","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib675","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3390\/ph12020078","article-title":"Tegsedi (inotersen): an antisense oligonucleotide approved for the treatment of adult patients with hereditary transthyretin amyloidosis","volume":"12","author":"Gales","year":"2019","journal-title":"Pharmaceuticals (Basel)"},{"issue":"13","key":"10.1016\/j.pharmr.2025.100065_bib676","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s40265-022-01765-5","article-title":"Vutrisiran: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib677","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ymgme.2019.03.002","article-title":"Pathogenesis and clinical features of the acute hepatic porphyrias (AHPs)","volume":"128","author":"Bonkovsky","year":"2019","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib678","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s13023-022-02314-9","article-title":"Challenges in diagnosis and management of acute hepatic porphyrias: from an uncommon pediatric onset to innovative treatments and perspectives","volume":"17","author":"Marcacci","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.pharmr.2025.100065_bib679","doi-asserted-by":"crossref","first-page":"24","DOI":"10.21037\/tgh-2020-01","article-title":"The acute hepatic porphyrias","volume":"6","author":"Wang","year":"2020","journal-title":"Transl Gastroenterol Hepatol"},{"key":"10.1016\/j.pharmr.2025.100065_bib680","doi-asserted-by":"crossref","DOI":"10.1016\/j.eurpolymj.2024.112866","article-title":"siRNA-mediated gene silencing for non-alcoholic fatty liver disease: a comprehensive review of molecular targets","volume":"208","author":"Mahmoudi","year":"2024","journal-title":"Eur Polym J"},{"key":"10.1016\/j.pharmr.2025.100065_bib681","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.2147\/DDDT.S281631","article-title":"Spotlight on givosiran as a treatment option for adults with acute hepatic porphyria: design, development, and place in therapy","volume":"16","author":"Majeed","year":"2022","journal-title":"Drug Des Devel Ther"},{"issue":"24","key":"10.1016\/j.pharmr.2025.100065_bib682","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1056\/NEJMe2010986","article-title":"Givosiran\u2014running RNA interference to fight porphyria attacks","volume":"382","author":"Gonzalez-Aseguinolaza","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib683","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40291-019-00438-6","article-title":"Leading RNA Interference therapeutics part 2: silencing delta-aminolevulinic acid synthase 1, with a focus on givosiran","volume":"24","author":"de Paula Brand\u00e3o","year":"2020","journal-title":"Mol Diagn Ther"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib684","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40265-023-01987-1","article-title":"Lumasiran: a review in primary hyperoxaluria type 1","volume":"84","author":"Kang","year":"2024","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100065_bib685","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s40256-021-00477-7","article-title":"A critical review of the efficacy and safety of inclisiran","volume":"21","author":"Hardy","year":"2021","journal-title":"Am J Cardiovasc Drugs"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib686","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40265-021-01473-6","article-title":"Inclisiran: first approval","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100065_bib687","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1007\/s10620-020-06437-6","article-title":"Two-dose hepatitis B vaccine (Heplisav-B) results in better seroconversion than three-dose vaccine (Engerix-B) in chronic liver disease","volume":"66","author":"Amjad","year":"2021","journal-title":"Dig Dis Sci"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100065_bib688","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2136912","volume":"18","author":"Girndt","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.pharmr.2025.100065_bib689","doi-asserted-by":"crossref","first-page":"6529","DOI":"10.1016\/j.vaccine.2021.09.050","article-title":"Serological response with Heplisav-B\u00ae in prior Hepatitis B vaccine non-responders living with HIV","volume":"39","author":"Khaimova","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.pharmr.2025.100065_bib690","series-title":"The US agency rejected the expanded use of Dynavax\u2019s vaccine for adults on haemodialysis, citing insufficient efficacy and safety data","author":"Deswal","year":"2024"},{"key":"10.1016\/j.pharmr.2025.100065_bib691","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41587-025-02555-6","article-title":"Fresh from the biotech pipeline: FDA approvals settle in 2024, but what next?","volume":"43","author":"Senior","year":"2025","journal-title":"Nat Biotechnol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib693","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3390\/ph18030291","article-title":"2024 FDA TIDES (peptides and oligonucleotides) harvest","volume":"18","author":"Al Musaimi","year":"2025","journal-title":"Pharmaceuticals"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100065_bib694","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s40265-024-02080-x","article-title":"Imetelstat: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"issue":"22","key":"10.1016\/j.pharmr.2025.100065_bib696","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.2217\/fon-2022-0235","article-title":"Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design","volume":"18","author":"Mascarenhas","year":"2022","journal-title":"Future Oncol"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100065_bib697","doi-asserted-by":"crossref","first-page":"6918","DOI":"10.1097\/MS9.0000000000002698","article-title":"Imetelstat (Rytelo): a promising treatment for adults with lower-risk MDS and transfusion-dependent anemia","volume":"86","author":"Ahmed","year":"2024","journal-title":"Ann Med Surg (Lond)"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib698","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.3390\/ijms24032700","article-title":"A comprehensive review of mRNA vaccines","volume":"24","author":"Gote","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib699","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s15010-020-01516-2","article-title":"COVID-19 outbreak: history, mechanism, transmission, structural studies and therapeutics","volume":"49","author":"Yesudhas","year":"2021","journal-title":"Infection"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib700","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41392-022-00907-1","article-title":"The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication","volume":"7","author":"Ning","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib701","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01948-2020","article-title":"Elevated ACE-2 expression in the olfactory neuroepithelium: implications for anosmia and upper respiratory SARS-CoV-2 entry and replication","volume":"56","author":"Chen","year":"2020","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100065_bib702","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s00408-020-00408-4","article-title":"ACE2: the major cell entry receptor for SARS-CoV-2","volume":"198","author":"Scialo","year":"2020","journal-title":"Lung"},{"key":"10.1016\/j.pharmr.2025.100065_bib703","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120586","article-title":"mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability","volume":"601","author":"Schoenmaker","year":"2021","journal-title":"Int J Pharm"},{"issue":"19","key":"10.1016\/j.pharmr.2025.100065_bib704","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1056\/NEJMoa2113017","article-title":"Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase","volume":"385","author":"El Sahly","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100065_bib705","article-title":"A novel mRNA vaccine, SYS6006, against SARS-CoV-2","volume":"13","author":"Xu","year":"2022","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib706","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nbt.1602","article-title":"Rational design of cationic lipids for siRNA delivery","volume":"28","author":"Semple","year":"2010","journal-title":"Nat Biotechnol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib707","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.1016\/S2666-5247(21)00280-9","article-title":"Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"3","author":"Chen","year":"2022","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.pharmr.2025.100065_bib708","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.cell.2020.07.024","article-title":"A thermostable mRNA vaccine against COVID-19","volume":"182","author":"Zhang","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib709","doi-asserted-by":"crossref","first-page":"41","DOI":"10.14348\/molcells.2023.2165","article-title":"Development of mRNA vaccines\/therapeutics and their delivery system","volume":"46","author":"Son","year":"2023","journal-title":"Mol Cells"},{"key":"10.1016\/j.pharmr.2025.100065_bib710","series-title":"Respiratory Syncytial Virus Vaccine","year":"2024"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100065_bib711","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1016\/j.ymthe.2024.06.031","article-title":"The tricky second album: Licensure of an mRNA vaccine for respiratory syncytial virus","volume":"32","author":"Tregoning","year":"2024","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib712","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/s41467-019-08329-4","article-title":"Engineered transfer RNAs for suppression of premature termination codons","volume":"10","author":"Lueck","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.pharmr.2025.100065_bib713","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.omtn.2022.04.033","article-title":"Efficient suppression of endogenous CFTR nonsense mutations using anticodon-engineered transfer RNAs","volume":"28","author":"Ko","year":"2022","journal-title":"Mol Ther Nucleic Acids"},{"issue":"7966","key":"10.1016\/j.pharmr.2025.100065_bib714","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41586-023-06133-1","article-title":"Engineered tRNAs suppress nonsense mutations in cells and in vivo","volume":"618","author":"Albers","year":"2023","journal-title":"Nature"},{"issue":"7351","key":"10.1016\/j.pharmr.2025.100065_bib715","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nature10165","article-title":"Converting nonsense codons into sense codons by targeted pseudouridylation","volume":"474","author":"Karijolich","year":"2011","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib716","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.molcel.2023.01.009","article-title":"Targeted pseudouridylation: an approach for suppressing nonsense mutations in disease genes","volume":"83","author":"Adachi","year":"2023","journal-title":"Mol Cell"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib717","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/(SICI)1098-1004(1998)11:4<332::AID-HUMU16>3.0.CO;2-P","article-title":"Analysis of five mutations in 20 mucopolysaccharidosis type I patients: high prevalence of the W402X mutation","volume":"11","author":"Gort","year":"1998","journal-title":"Hum Mutat"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib718","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.molcel.2022.11.011","article-title":"CRISPR-free, programmable RNA pseudouridylation to suppress premature termination codons","volume":"83","author":"Song","year":"2023","journal-title":"Mol Cell"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100065_bib719","doi-asserted-by":"crossref","DOI":"10.1186\/gb-2011-12-11-r118","article-title":"Hundreds of putatively functional small open reading frames in Drosophila","volume":"12","author":"Ladoukakis","year":"2011","journal-title":"Genome Biol"},{"key":"10.1016\/j.pharmr.2025.100065_bib720","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.03528","article-title":"Extensive translation of small open reading frames revealed by Poly-Ribo-Seq","volume":"3","author":"Aspden","year":"2014","journal-title":"Elife"},{"key":"10.1016\/j.pharmr.2025.100065_bib721","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.03523","article-title":"Long non-coding RNAs as a source of new peptides","volume":"3","author":"Ruiz-Orera","year":"2014","journal-title":"Elife"},{"key":"10.1016\/j.pharmr.2025.100065_bib722","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.703374","article-title":"Exploring evidence of non-coding RNA translation with Trips-Viz and GWIPS-Viz browsers","volume":"9","author":"Zaheed","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.pharmr.2025.100065_bib723","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1166\/jpsp.2017.1070","article-title":"Decoding of non-coding DNA and non-coding RNA: pri-micro RNA-encoded novel peptides regulate migration of cancer cells","volume":"3","author":"Fang","year":"2017","journal-title":"J Pharm Sci Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib724","doi-asserted-by":"crossref","first-page":"4475","DOI":"10.1038\/s41467-018-06862-2","article-title":"A peptide encoded by circular form of LINC-PINT suppresses oncogenic transcriptional elongation in glioblastoma","volume":"9","author":"Zhang","year":"2018","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib725","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.cell.2019.05.010","article-title":"The translational landscape of the human heart","volume":"178","author":"van Heesch","year":"2019","journal-title":"Cell"},{"issue":"6172","key":"10.1016\/j.pharmr.2025.100065_bib726","doi-asserted-by":"crossref","DOI":"10.1126\/science.1248636","article-title":"Toddler: an embryonic signal that promotes cell movement via Apelin receptors","volume":"343","author":"Pauli","year":"2014","journal-title":"Science"},{"issue":"6335","key":"10.1016\/j.pharmr.2025.100065_bib727","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1126\/science.aam9361","article-title":"Control of muscle formation by the fusogenic micropeptide myomixer","volume":"356","author":"Bi","year":"2017","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100065_bib728","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.cell.2015.01.009","article-title":"A micropeptide encoded by a putative long noncoding RNA regulates muscle performance","volume":"160","author":"Anderson","year":"2015","journal-title":"Cell"},{"issue":"13","key":"10.1016\/j.pharmr.2025.100065_bib729","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1016\/j.celrep.2018.06.002","article-title":"Mitoregulin: a lncRNA-encoded microprotein that supports mitochondrial supercomplexes and respiratory efficiency","volume":"23","author":"Stein","year":"2018","journal-title":"Cell Rep"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib730","doi-asserted-by":"crossref","first-page":"428","DOI":"10.4049\/jimmunol.1900791","article-title":"A mitochondrial micropeptide is required for activation of the Nlrp3 inflammasome","volume":"204","author":"Bhatta","year":"2020","journal-title":"J Immunol"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100065_bib731","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.ymthe.2019.09.001","article-title":"ncRNA-encoded peptides or proteins and cancer","volume":"27","author":"Wang","year":"2019","journal-title":"Mol Ther"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100065_bib732","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/bioinformatics\/btp688","article-title":"sORF finder: a program package to identify small open reading frames with high coding potential","volume":"26","author":"Hanada","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.pharmr.2025.100065_bib733","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1186\/s12859-019-3033-9","article-title":"MiPepid: microPeptide identification tool using machine learning","volume":"20","author":"Zhu","year":"2019","journal-title":"BMC Bioinform"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100065_bib734","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1101\/gr.134767.111","article-title":"Long noncoding RNAs are rarely translated in two human cell lines","volume":"22","author":"B\u00e1nfai","year":"2012","journal-title":"Genome Res"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100065_bib735","doi-asserted-by":"crossref","first-page":"6839","DOI":"10.1038\/s41467-024-50301-4","article-title":"Rp3: Ribosome profiling-assisted proteogenomics improves coverage and confidence during microprotein discovery","volume":"15","author":"Vieira de Souza","year":"2024","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib736","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cub.2003.12.036","article-title":"A noncoding RNA is required for the repression of RNApolII-dependent transcription in primordial germ cells","volume":"14","author":"Martinho","year":"2004","journal-title":"Curr Biol"},{"issue":"7179","key":"10.1016\/j.pharmr.2025.100065_bib737","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nature06498","article-title":"Drosophila Pgc protein inhibits P-TEFb recruitment to chromatin in primordial germ cells","volume":"451","author":"Hanyu-Nakamura","year":"2008","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib738","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/nchembio.2249","article-title":"A human microprotein that interacts with the mRNA decapping complex","volume":"13","author":"D'Lima","year":"2017","journal-title":"Nat Chem Biol"},{"issue":"14","key":"10.1016\/j.pharmr.2025.100065_bib739","doi-asserted-by":"crossref","first-page":"6708","DOI":"10.1021\/jacs.0c00706","article-title":"Micropeptide MIAC inhibits HNSCC progression by interacting with Aquaporin 2","volume":"142","author":"Li","year":"2020","journal-title":"J Am Chem Soc"},{"issue":"34","key":"10.1016\/j.pharmr.2025.100065_bib740","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.1038\/s41388-018-0281-5","article-title":"The cancer-associated microprotein CASIMO1 controls cell proliferation and interacts with squalene epoxidase modulating lipid droplet formation","volume":"37","author":"Polycarpou-Schwarz","year":"2018","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib741","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.cell.2007.05.056","article-title":"Drosophila microRNAs are sorted into functionally distinct argonaute complexes after production by dicer-1","volume":"130","author":"F\u00f6rstemann","year":"2007","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100065_bib742","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.cell.2007.05.057","article-title":"Sorting of Drosophila small silencing RNAs","volume":"130","author":"Tomari","year":"2007","journal-title":"Cell"},{"issue":"19","key":"10.1016\/j.pharmr.2025.100065_bib743","doi-asserted-by":"crossref","first-page":"9850","DOI":"10.1093\/nar\/gks705","article-title":"microRNAs associated with the different human Argonaute proteins","volume":"40","author":"Dueck","year":"2012","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100065_bib744","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1101\/gad.182758.111","article-title":"Quantitative functions of Argonaute proteins in mammalian development","volume":"26","author":"Wang","year":"2012","journal-title":"Gene Dev"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100065_bib745","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.4161\/rna.21083","article-title":"Distinct AGO1 and AGO2 associated miRNA profiles in human cells and blood plasma","volume":"9","author":"Turchinovich","year":"2012","journal-title":"RNA Biol"},{"key":"10.1016\/j.pharmr.2025.100065_bib746","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1016\/j.ymthe.2018.08.022","article-title":"Therapeutic potential of OMe-PS-miR-29b1 for treating liver fibrosis","volume":"26","author":"Kumar","year":"2018","journal-title":"Mol Ther"}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699725074733?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699725074733?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T23:01:48Z","timestamp":1759964508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031699725074733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":741,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0031699725074733"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmr.2025.100065","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmaceutical perspectives on oligonucleotide therapeutics and delivery systems","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmr.2025.100065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100065"}}